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ABSTRACT 
 
Harshman, Sean William. M.S., Department of Pharmacology Toxicology, Wright State 
University, 2009. 
Effects of Chlorpyrifos-oxon on Prohormone Convertase Enzyme Activity. 
 
 
 
 Organophosphate (OP) compounds have been synthesized for various applications 
including medicine, pest control and weapons of terror.  OPs irreversibly phosphorylate 
the active site of acetylcholinesterase, the primary target of toxicity, rendering it inactive 
causing a hypercholinergic state in the post synaptic cleft.  However, very little is known 
about the effects of OPs on secondary targets of toxicity i.e. other serine hydrolases.  The 
prohormone convertase (PC) enzymes, specifically PC1/3 and PC2, are serine hydrolases 
which are responsible for the processing of pro-opiomelanocortin in the anterior and 
intermediate lobes of the pituitary.  To test the direct interaction between OPs and the PC 
enzymes, purified PC1/3 and PC2 were treated in vitro with chlorpyrifos-oxon (CHP-O) 
or vehicle, acetonitrile (ACN), endoproteolyically digested, and analyzed for any 
evidence of phosphorylation on a MALDI-TOF/TOF mass spectrometer (MS).  To 
further describe the interaction, enzyme assays was performed by pretreating the purified 
PC1/3 and PC2 with micromolar concentrations of CHP-O over 0.5 h – 4 h.  Substrate 
was added, adrenocorticotropic hormone 1-39 (ACTH 1-39), and analyzed on the 
MALDI-TOF/TOF MS for processing products and any subsequent reduction in peptide 
production caused by CHP-O.  As a result of these experiments, a statistically significant 
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(p <0.05) reduction in peptide processing was observed for both PC1/3 and PC2 in the 
presence of CHP-O in vitro.  However, evidence of direct interaction of CHP-O on the 
PC enzymes was inconclusive.  
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STATEMENT OF THE PROBLEM 
Previous data recorded in the Cool lab suggests that dermal exposures of 
chlorpyrifos (CHP) in rats can cross the blood brain barrier and accumulate, resulting in a  
reduction of acetylcholinesterase (AChE) activity [1].  Further evidence of AChE 
inhibition by CHP in the pre-frontal cortex and hippocampus was demonstrated by the 
Cool lab and provides sufficient proof of the possible inhibition of other serine 
hydrolases in that locality i.e. the prohormone convertase enzymes [1].  We propose that 
the prohormone convertase enzymes, PC1/3 and PC2, will be inhibited by CHP when 
treated in vitro.  Furthermore, the processing activity of PC1/3 and PC2 will be reduced 
in the presence of CHP under in vitro conditions.  
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INTRODUCTION 
ORGANOPHOSPHATE HISTORY AND SIGNIFICANCE FOR STUDY 
Since the 1930’s, anticholinesterase compounds, organophosphates (OPs) and 
carbamate, have been synthesized for numerous applications including therapeutics, pest 
control (pesticides) and chemical warfare (nerve agents) [2, 3].  Initially carbamate 
compounds, reversible inhibitors of acetylcholinesterase, were discovered and 
synthesized for treatment of myasthenia gravis, glaucoma and Alzheimer’s disease [4 - 
6].  However, further work with anticholinesterase compounds lead to the discovery of 
irreversible acetylcholinesterase compounds, OPs. 
Of interest, the pesticide chlorpyrifos (CHP), O,O-diethyl O-(3,5,6-trichloro-2-
pyridyl)phosphorothioate, known under the trade names Dursban®, Lorsban® Empire20®, 
Equity®, and Whitmire PT 270®, is one of the most widely applied pesticides used in 
agriculture today (Figure 1) [7].   Currently, CHP is available for use in 98 countries [7]. 
Chlorpyrifos is utilized for pest control of field crops, citrus fruits, tree nuts, and 
vegetables such as corn, wheat, cranberries, strawberries, apples, figs, peaches, cherries, 
grapes, walnuts, almonds, broccoli, cabbage and peanuts [7, 8].   
Domestically, CHP ranked among the top organophosphate insecticides in 
agricultural and non-agricultural use from the mid-80’s thru 2000 [7, 8].  From 1987 to 
1998, an estimated 21 to 24 million pounds of chlorpyrifos were used annually with more 
than half of the use in residential settings [8].  However in June of 2000, under the Food 
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Quality Protection Act of 1996, the Environmental Protection Agency (EPA) banned the 
in-home and around-home registered use and sales of chlorpyrifos [7, 8].  Conversely, the 
EPA has continued to allow the registration of chlorpyrifos for use on agriculture, golf 
courses, road medians, industrial sites, wood treatments, and various public health needs 
to name a few [8].   
As a result of this continued and relatively wide spread use, organophosphate 
insecticides have accounted for 756 accidental exposures as reported to poison control 
centers in 2007, which is down from 12,250 in 1998 due to the EPA ban [8 – 10].  Of the 
794 overall organophosphate insecticide exposures, 150 were to those less than 6 years 
old [10].  This exposure incidence to the young is of high concern.  Data has shown that 
children are more susceptible to CHP toxicity due to lower expression of paraoxonase 
and carboxylesterase levels at earlier ages [11].  However, insecticides are not the only 
organophosphate compounds that have been used historically and continue to pose a 
constant threat to children and adults alike.   
Nerve agents, developed initially as chemical weapons during WWII, have 
received continuous interest by terrorists due to their historical uses as weapons of 
terror/mass destruction [12, 13].  Most notable is sarin, 2-(fluoro-methyl-
phosphoryl)oxypropane, which is an organophosphate compound that was first 
synthesized by Gerhard Schrader in 1938 [12, 13].  Sarin is highly toxic and the most 
volatile of the German nerve agents (Figure 1) [12].   Because of these two properties, 
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production of the chemical agent was banned by the Chemical Weapons Convention of 
1993 [14].  However, sarin has been historically released as chemical warfare and as a 
weapon of terror in various settings throughout the world [12, 13]. 
Although sarin was first discovered and produced during WWII, the German 
government did not utilize the weapon during battle [12, 13].  The first reported use of 
sarin was in 1987 and 1988 during the Iran-Iraq war [15].  During this time, Saddam 
Hussein reportedly released sarin in conjunction with sulfur mustard, a vesicant, and 
potentially other chemical agents on Kurdish villages in Northern Iraq [15].  Reports 
suspect up to 5,000 fatalities and 65,000 injuries from these attacks [15]. 
More recently, in the mid 90’s, two attacks were made by the radical Japanese 
Buddhist sect Aum Shinrikyo on the Japanese public [15, 13].  First, in 1994, the cult 
released sarin in an apartment complex in the city of Matsumoto killing 7 and injuring 
300 in the incident [12, 13, 16].  More notably, in March of the following year, the sect 
released homemade sarin in a Tokyo subway killing 12 and injuring 5,500 [13, 16].  
However, these sorts of attacks have not been the last. 
In May of 2004, the U.S. government gave confirmation that an artillery shell 
used as a roadside bomb in Iraq reportedly contained between 3 and 4 liters of sarin [17].   
Two soldiers were treated for nerve agent exposure after showing the common symptoms 
following the attack [17].  To this end, aging stock piles of sarin are housed by various  
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Figure 1: Organophosphate Molecular Structures.  A) General organophosphate 
molecular structure.  B) Sarin molecular structure.  C) Chlorpyrifos molecular structure.  
D) Chlorpyrifos-oxon molecular structure [2, 18]. 
 
A B 
C D 
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countries including Russia, the United States, Iraq, and possibly Iran, North Korea, Syria, 
and Libya [14, 16].  As a result of these stockpiles, sarin may pose an immediate threat 
until countries eliminate the chemical stock, or ensure it is no longer produced [14, 16].   
From these relatively recent exposures and large stockpiles housed throughout the 
world, the threat for release of sarin and other OP nerve agents continues to exist today.  
Furthermore, human exposures to OP pesticides still continue to be reported with high 
frequency annually due to their continued use in agriculture.  To this end, further 
investigation into the effects of irreversible anticholinesterase compounds, pesticides and 
nerve agents, on human exposures is warranted. 
 
ORGANOPHOSPHATE STRUCTURE AND MECHANISM OF ACTION 
Organophosphate compounds all share a similar structure [19].  The OP molecule 
contains a central phosphorus atom, surrounded by a phosphoryl or thiophosphoryl bond, 
two alkyl groups (R1 & R2) and what is termed a “leaving group” (X) (Figure 1) [2, 19].  
The phosphoryl and thiophosphryl bond determines the immediate toxicity of the 
compound [19].  A thiophosphorylated compound must be biologically desulfurated to an 
oxon form (=O) for the greatest toxicological effects to be observed [2, 19].  As with 
chlorpyrifos, the oxon form of the molecule is approximately three orders of magnitude 
more potent at inhibiting the main target of toxicity than the sulfonated form (Figure 1) 
[20]. 
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Figure 2: Metabolism of chlorpyrifos.  Chlorpyrifos can be metabolized into two 
pathways mediated by cytochrome P-450 enzymes.  Detoxification can occur by 
dearylation into the diethylthiophosphate and 3,5,6-trichloropyridinol metabolites and 
conjugation to glucuronide and sulfate molecules for excretion.  Metabolic activation can 
arise by desulfuration of chlorpyrifos into the oxon form.  The oxon form is a potent 
inhibitor of acetylcholinesterase.  The free oxon can be further broken down into 
diehylphosphate and 3,5,6-trichloropyridinol and excreted as a glucuronide or sulfate 
conjugate [11].   
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  The biotransformation of thiophosphyroylated OPs occurs metabolically by 
cytochrome P450 (CYP) enzymes of hepatocytes [2, 19 – 21].  For example, the 
chlorpyrifos molecule has two metabolic pathways in humans which it can follow, 
detoxification or activation [7].  Detoxification occurs by way of dearylation of the parent 
molecule to the inactive metabolite 3,5,6-trichloro-2-pyridinol (TCP), diethyl phosphate, 
and diethyl thiophosphate (Figure 2) [7, 20, 21].  This process is largely mediated by the 
CYP isoforms 2C19 and 3A4 [20, 21].  Conversely, metabolic activation can occur by 
desulfuration of the parent compound into the oxon form with transformation primarily 
completed by CYP2B6 and CYP3A4 (Figure 2) [20, 21].  The active oxon metabolite is 
highly electrophillic [19].  As a result, the chlorpyrifos-oxon (CHP-O) has increased 
affinity and potency within the main target, acetylcholinesterase (AChE), producing the 
greatest toxicological effects [2, 19, 22].   
Acetylcholinesterase is a serine hydrolase responsible for the hydrolysis of the 
ester bond in acetylcholine to acetic acid and choline in the neuronal synapse (Figure 3) 
[22].  Organophosphates, like chlorpyrifos and sarin, covalently phosphorylate the 
hydroxyl group of the serine in the catalytic domain of AChE (Figure 3) [19, 22, 23].  
Over time, several minutes to hours depending on the OP, the bound organophosphate 
can become dealkylated by the removal of an R group, in a process that is termed as 
“aging” [19, 22, 23].  Once aging occurs, the OP becomes permanently bound to AChE 
rendering the enzyme disfunctional [19, 22].  Synthesis of a new acetylcholinesterase  
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Figure 3:  Acetylcholinesterase function and OP interaction.  A) Acetylcholinesterase 
normal function.  An illustration of the break down of acetylcholine to acetic acid and 
choline by acetylcholinesterase.  B)  Inhibition of acetylcholinesterase by an 
organophosphate compound.  An illustration of phoshporylation of the active site serine 
by the OP [23]. 
A B 
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 molecule must occur to replace the phosphorylated enzyme which can take upwards of 3 
to 4 days [12, 19, 22, 24].   
 The OP-AChE complex causes a hypercholinergic effect at the nerve terminal 
[19, 22].  Low dose exposures have shown mild symptoms, sweating, miosis, rhinorrhea, 
nausea, and vomiting [19, 22].  In contrast, in addition to the low dose symptoms, high 
dose exposures of organophosphates have been shown to cause seizures, asphyxiation, 
increased heart rate, and increase in fluid excretion ultimately leading to death [19, 22].  
Moreover, studies have shown that persistent lasting effects, intermediate syndrome and 
delayed polyneuropathy, can last up to several months, following an acutely high dose 
exposure [25].  The mechanism for the presence of delayed effects is much debated [25, 
26].   
Phosphorylation and the resultant inhibition of AChE is the primary target of 
organophosphate compounds [12, 19, 22].  However, acetylcholinesterase inhibition 
cannot fully account for all the symptoms observed in an OP exposure [12].  To that end, 
there are approximately 1227 hydrolases in the human body, with about 150 of those 
being serine hydrolases [27]. These additional serine hydrolases can potentially be 
affected by organophosphate compounds as secondary targets of toxicity [22, 28]. 
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Figure 4: The structural domains of PC1/3 and PC2.  The active sites of each enzyme 
contain a catalytic triad consisting of an Asp-His-Ser moiety.  This triad is in close 
relation to that of acetylcholinesterase, Glu-His-Ser.  This relationship leads to the belief 
that organophosphate compounds will inhibit the PC enzymes in a similar fashion as they 
do to acetylcholinesterase [29]. 
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PROHORMONE CONVERTASE ENZYMES AND PEPTIDE PROCESSING 
The serine hydrolases of interest, for the Cool lab, with relation to 
organophosphate toxicity are the prohormone convertase (PC) enzymes of the regulated  
neuroendocrine system.  More specifically prohormone convertase 1 (PC1/3) and 
prohormone convertase 2 (PC2).   
PC1/3 and PC2 are quite similar structure (Figure 4) [30 – 34]. Each enzyme 
consists of an amino-terminal signal peptide, responsible for signaling entry into the 
regulated secretory pathway, a propeptide region, which assists in folding of the protein, 
a catalytic domain, which includes a catalytic triad similar to AChE, and a conserved 
domain, called the P-domain (Figure 4) [29 – 34].  The P-domain is responsible for 
structural stability and regulation of the catalytic domain [30 – 34].  It is the similarity 
between the active sites of AChE, Glu-His-Ser, and the PC enzymes, Asp-His-Ser, most 
notably the serine moiety, which would suggest PC enzymes could also become inhibited 
in the presence of organophosphate compounds [29].  
Biologically, PC1/3 and PC2 are responsible for processing, or cleavage, of 
prohormones into biologically active peptide hormones in neuroendocrine cells of the 
posterior, anterior and intermediate lobes of the pituitary as part of the regulated secretory 
pathway of the trans-Golgi network [30 – 34].  The prohormone converting enzymes  
13 
 
Figure 5: The PC1/3 and PC2 enzymatic processing of pro-opiomelanocortin.                 
 indicates a location of cleavage by the corresponding enzyme.  Abbreviations: NTP: N-
terminal peptide, γ-MSH: γ-Melanocyte stimulating hormone, JP: Joining peptide, α-
MSH: α-Melanocyte stimulating hormone, CLIP: Corticotropic like intermediate peptide, 
ACTH: Adrenocorticotropic hormone, β-MSH: β-Melanocyte stimulating hormone [30, 
36]. 
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cleave neuroendocrine propeptides at pairs of basic residues (Lys – Arg) or (Arg – Arg) 
on the C-terminal side of the propeptide liberating the active peptide [30 – 34].  PC1/3 
and PC2 have been shown to be involved in processing of prohormones in the insulin, 
glucagon, cholecystokinin, gastrin, dynorphin, enkephalin, thyrotropin-releasing 
hormone, neurotensin, vasopressin, oxytocin and somatostatin pathways [35].  However, 
the most relevant processing by PC1/3 and PC2, for the Cool lab, occurs in the anterior 
and intermediate lobes of the pituitary by way of cleavage of pro-opiomelanocortin 
(POMC) into various other biologically active peptide hormones [36]. 
Both PC1/3 and PC2 process POMC to adrenocorticotropic hormone (ACTH) 
(Figure 5) [36].  However, PC2, mainly in the intermediate lobe, can further process 
ACTH into α-melanocite stimulating hormone (α-MSH) and corticotropic like 
intermediate peptide (CLIP) (Figure 5) [36].  In addition to α-MSH and CLIP, PC2 can 
also produce β-lipotropin, β-MSH, β-endorphin, γ-MSH and γ-liportropin from the 
POMC proprotein (Figure 5) [36].  Varying degrees of knowledge exist for the 
physiological uses of each liberated peptide hormones from POMC.  However, ACTH 
has been studied rather extensively.   
ACTH is secreted in response to physical, emotional, and chemical stressors in 
addition to normal circadian rhythm [37].  It is mainly responsible for inducing 
production of the glucorticoid coritsol in the adrenal cortex [37].  Coritsol is involved in 
the maintenance and regulation of plasma glucose levels in the body [37].  However, 
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ACTH not only stimulates glucocorticoid production, it also stimulates, to a lesser extent, 
the production of the mineral coriticoid aldosterone [37].  Aldosterone, a steroid 
hormone, is responsible for the homeostasis of water and salt levels circulating in the 
body [37].   
Disruption in the production of ACTH and the subsequent active peptides of 
POMC caused by the inhibition of prohormone convertase processing could cause many 
severe symptoms marked by hypoadrenalism [38].  Deficiency in ACTH production can 
result in adrenal failure [39].  Symptoms of adrenal failure include lethargy, weakness, 
nausea, vomiting, dehydration, orthostatic hypotension, coma and death if untreated [39].                                                                                                                 
Under normal physiological conditions, processing of precursor peptide hormones 
by PC1/3 and PC2 occurs in the secretory granules of the trans-Golgi network [30 – 34].  
However, disruption of peptide processing by organophosphates, especially that of 
POMC, could have profound effects on an organism’s steroidal production in the adrenal 
cortex [37].  All the symptoms of an OP exposure cannot be fully explained by inhibition 
of AChE alone [12].  Therefore, other factors must be affected by the exposure.  To that 
end, it is currently unknown what effect organophosphate compounds will have on 
peptide hormone processing and enzymatic activity of the prohormone convertase 
enzymes. 
16 
 
HYPOTHESIS 
Prohormone converting enzymes (PCs) are serine hydrolases that have a common 
Asp-His-Ser motif at their active sites.  The similarity of this Glu-His-Ser motif to that of 
AChE strongly suggests that PCs could be inhibited by organophosphate compounds, 
such as chlorpyrifos-oxon. We are interested in whether the prohormone processing 
enzymes, PC1/3 and PC2, can be modified by CHP-O and whether this modification 
would lead to inhibition of their enzyme activity.  Thus, the hypothesis is that 
organophosphates can modify the prohormone convertase enzymes at their active site to 
cause a decrease in enzyme activity and peptide hormone production. This hypothesis 
will be tested using in vitro modification of the purified enzymes for active site inhibition 
and enzyme activity. 
 
SPECIFIC AIMS 
1)  Test the hypothesis that prohormone converting enzymes PC1/3 and PC2 are modified 
by chlorpyrifos-oxon molecule. 
2)  Test the hypothesis that prohormone convertase enzyme activity is reduced by 
chlorpyrifos-oxon molecule.  
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MATERIALS AND METHODS 
ENDOPROTEASE DIGESTION OF PROHORMONE CONVERTASE 1/3 
 To determine whether the chlorpyrifos-oxon molecule covalently binds to the 
active site serine of PC1/3 in vitro, 10 µg of recombinant human prohormone convertase 
1/3 (rhPC1/3, R&D Systems, >95% purity) was suspended in 200 µL of 100 mM 
ammonium bicarbonate (NH4HCO3, Fisher) buffer (aq) at pH 7.8 in the top of a 30,000 
molecular weight cut off spin filter (Millipore, Microcon YM-30).  Samples were 
challenged by a pretreatment incubation by the addition of 1µL of vehicle, acetonitrile 
(ACN, Fisher, ACS Grade), or 500 mM CHP-O (ChemService, 99.1%) for a period of 3 
h at 37°C with gentle shaking (~500 rpm) [40, 41].  After the pretreatment time, the 
samples and control were spun at ~10,000 G for 10 min [41].  Remaining solution was 
collected from the filter by adding 100 µL 100 mM NH4HCO3 buffer, inverting filter in a 
new tube and spinning at ~1,000 G for 5 min.  2 µL of 0.5 µg/µL endoproteinase Glu-C 
(Proteomics grade, V8, Sigma) was added to each sample and control.  Samples were 
returned to the 37°C heating block with gentle shaking for 18 h.  Solutions were removed 
from the heating block and 10 µL of 10% trifloroacetic acid (TFA, Pierce, ≥99.5%) was 
added to each sample to quench the reaction.  Samples were frozen until analyzed.   
Samples were thawed and vacuum concentrated to approximately 20 µL – 30 µL.  
Concentrated samples were desalted by the use of a C18 resin ZipTip (Millipore, 
ZTC18S096).  ZipTips are primed by aspirating and dispensing 90% methanol (aq) 
(MeOH, Fisher, ACS Grade) and 0.1% TFA (aq) 5 - 10 times each.  Peptide samples are 
bound by aspirating and dispensing sample solution 20 times.  Salts are removed from 
bound peptides by aspirating and dispensing 0.1% TFA (aq) 3 times.  Finally, elution of 
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bound peptides is completed by aspirating and dispensing the Zip Tip in 80% 
ACN:0.3%TFA (aq) 5 - 10 times.  1 µL of Zip Tip elution was spotted on a Bruker MTP 
384 well ground steel target plate (PN: 209519) [42, 43].  Spot were allowed to dry and 
overlaid with 1 µL of 10 mg/mL 2,5-dihydroxybenzoic acid (50%ACN:1%TFA) (aq) 
(DHB, Fluka, >99.5%) [42, 43].  Spot allowed to completely dry [42, 43].   
 Spotted samples were analyzed for PC1/3 digestive fragments produced by Glu-C 
on a Bruker AutoFlex III Martix Assisted Laser Desorption Ionization Time of Flight 
(MALDI-TOF) mass spectrometer (MS) in reflective positive ion mode utilizing an 
external calibration method.  Mass spectra were captured with a laser intensity of 15% 
and an acceleration voltage of 20kV.  1200 laser shots were added together to produce a 
single mass spectra.  Peaks corresponding to the theoretical cleavages of PC1/3 by Glu-C 
were selected and searched in the MASCOT database for homologous sequences.  
 
ENDOPROTEASE DIGESTION OF PROHORMONE CONVERTASE 2 
 To determine if chlorpyrifos-oxon phosphorylates PC2 in vitro, 5 µg – 10 µg of 
PC2 (generous gift from Dr. Iris Lindberg, University of Maryland) was suspended in 
100 µL of 100 mM NH4HCO3 buffer (aq) at pH 7.8.  Samples were challenged by a 
pretreatment incubation by the addition of 1 µL of vehicle, ACN, or 100 mM CHP-O for 
a period of 3 h at 37°C with gentle shaking [40, 41].  After the pretreatment time, 2 µL of 
0.5 µg/µL endoproteinase Glu-C was added to each sample and control.  Samples were 
returned to the 37°C heating block with gentle shaking for 18 h.  Solutions were removed 
from the heating block and 10 µL of 10% TFA was added to each sample to quench the 
reaction.   
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Samples were vacuum concentrated to approximately 20 µL – 30 µL and desalted 
by the use of a C18 resin ZipTip as described for the PC1/3 digestion.  1 µL of the ZipTip 
elution was spotted on a Bruker MTP 384 well ground steel target plate [42, 43].  Spots 
were allowed to air dry and overlaid with 1 µL of 10 mg/mL DHB (50%ACN:1%TFA) 
(aq) [42, 43].  Spots were completely dried.   
 Spotted samples were analyzed for PC2 digestive fragments produced by Glu-C 
on a Bruker AutoFlex III MALDI-TOF MS in reflective positive ion mode utilizing an 
external calibration method.  Mass spectra were captured with a laser intensity of 15% 
and an acceleration voltage of 20kV.  1200 laser shots were added together to produce a 
single mass spectra.  Peaks corresponding to the theoretical cleavages of PC2 by Glu-C 
were selected and searched in the MASCOT database for homologous sequences.  
 
PROHORMONE CONVERTASE 1/3 ACTIVITY ASSAY  
 To determine whether the CHP-O molecule reduces the activity of prohormone 
convertase 1/3 in-vitro, 1 µg of rhPC1/3 was suspended in 100 µL of 25 mM 2-[N-
Morpholino]ethanesulfonic acid⋅5 mM Calcium Chloride (MES·CaCl2, Sigma·Sigma) 
(aq) at pH 5 [44].  In duplicate, samples were pretreated by the addition of 1 µL vehicle, 
ACN, 1 mM CHP-O or 10 mM CHP-O, a 10 µM and 100 µM in solution final 
concentration of CHP-O, for 1 h to 4 h at 37°C (the 3 h pretreatment, 10 µM dose, 
replicate 2, was compromised and only one replicate was used) [45].  Additionally, 
appropriate blank preparations of buffer/ACTH 1-39 and buffer/PC1/3 samples were 
prepared and treated with vehicle as above.  After the pretreatment period, the activity of 
the rhPC1 was challenged by the addition of 1 µg of ACTH 1-39 (mouse, rat, Bachem, 
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>95%) [44].  Processing was allowed to occur for 6 h at 37°C.  The reaction was 
quenched by the addition of 10 µL of 1% TFA [44]. 
 An aliquot, 10 µL, of each sample was spotted on a weak-cation exchange protein 
chip array (BioRad, CM-10) for 10 min (3x) to facilitate peptide binding.  Solution was 
removed and washed with 5µl of 0.1%TFA (aq).  Each spot was overlaid with 5 µL of 10 
mg/mL DHB in 50%ACN:1%TFA (aq) solution.  Spots were allowed to air dry at room 
temperature.   
Spotted samples were analyzed for PC1/3 processing products, ACTH 1-15 and 
ACTH 1-17 in linear positive ion mode on a Bruker AutoFlex III MALDI-TOF MS 
utilizing an external calibration method (Figure 6).  Laser intensity was set to 20% and 
the acceleration voltage was set at 20kV.  Approximately 50 spectra, 200 laser shots 
each, were taken.  The baselines were subtracted and the relative intensities, processing 
peak intensity vs. ACTH 1- 39 peak intensity, were calculated.  The relative intensities 
were put in numerical order and the six spectra from each sample preparation with the 
closest relatative intensities were saved, analyzed and graphed [47].  Utilizing Prism 
Graph Pad Software, an unpaired student’s t-test was used to determine if the means of 
the relative intensities of each treatment group were statistically significant (p <0.05) 
when compared to the vehicle. 
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Figure 6:  Processing of ACTH 1 – 39 by PC1/3 and PC2.   Indicates a potential 
location of cleavage by either PC1/3 or PC2.  Molecular weight values shown are based 
on the theoretical calculated values or the package insert value. 
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PROHORMONE CONVERTASE 2 ACTIVITY ASSAY 
To determine whether CHP-O reduces the activity of prohormone convertase 2 in 
vitro, approximately 1 µg of PC2 (presumed to be 0.5 µg/µL) was suspended in 100 µL 
of assay buffer, 0.1 M sodium acetate, 2 mM CaCl2, 0.1% NaN3, 0.2% octyl glucosidase, 
0.1 mg/mL bovine serum albumin at pH 5.0 (assay buffer, a generous gift from Dr. Iris 
Lindberg, University of Maryland) [46].  Samples were pretreated by the addition of 1 µL 
vehicle, ACN, 1 mM CHP-O or 10 mM CHP-O, a 10 µM and 100 µM in solution final 
concentration, for 0.5 to 4 h at 37°C [45].  Additionally, appropriate blank preparations of 
buffer/ACTH 1-39 and buffer/PC2 samples were prepared and treated with vehicle as 
above.  After the pretreatment period, the activity of the PC2 was challenged by the 
addition of 1 µg ACTH 1-39 [46].  Processing was allowed to occur for 6 h at 37°C.  The 
reaction was quenched by the addition of 10 µL of 10% TFA [44].  Samples were spotted 
on a weak-cation exchange protein chip as described above for PC1/3. 
 Spotted samples were analyzed for PC2 processing products, ACTH 1-17 and 
ACTH 18-39, in reflected positive ion mode on the Bruker AutoFlex III MALDI-TOF 
MS utilizing an external calibration method (Figure 6).  Laser intensity was set at 15% 
and the acceleration voltage was 20kV. Approximately 50 spectra, 200 laser shots each, 
were taken.  The baselines were subtracted and the relative intensities, processing peak 
intensity vs. ACTH 1- 39 peak intensity, were calculated.  The relative intensities were 
put in numerical order and the six spectra from each sample preparation with the closest 
relatative intensities were saved, analyzed and graphed [47].  Utilizing the Prism Graph 
Pad Software, an unpaired student’s t-test was used to determine if the means of the 
relative intensities of each treatment group were statistically significant (p <0.05) when 
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compared to the vehicle. 
 
PC2 ACTIVITY ASSAY WITH OXIME TREATMENT 
 Oximes like pralidoxime-2-chloride (2-PAM) are given as a countermeasure 
against acute OP intoxication [12].  They are considered cholinesterase reactivators [12].  
Compounds like 2-PAM work by neuclophilic attack on the enzyme bound phosphorous 
of an OP, creating a phosphor-oxime intermediate, and there by reactivating the enzyme 
[48].  This process is limited by concentration of oxime, ring structure of the oxime, and 
aging characteristics of the OP bound to the enzyme [48].  Testing of various oximes has 
been conducted to determine the efficiency of reactivation AChE [49, 50].  However, it is 
currently unknown what effect oximes, specifically 2-PAM, would have on the 
prohormone convertase enzymes, specifically PC2. 
To assess if oxime treatment reactivates the processing capabilities of PC2 in-
vitro, samples and controls were prepared in duplicate as described below. 
 Buffer PC2 ACN CHP-O 
Control - 1 97 µL 2 µL 1 µL - 
Control - 2 97 µL 2 µL - 1 µL 
Control - 3 97 µL 2 µL 1 µL - 
     
Sample -1  97 µL 2 µL - 1 µL 
Sample -2 97 µL 2 µL - 1 µL 
     
Samples and controls were placed in a 37ºC incubator for 3 h to facilitate CHP-O binding 
[45].  Solutions were removed and treated with either assay buffer or 10 mM, 50 µM and 
100 µM in solution concentration, 2-PAM (generous gift from Dr. James Lucot) for 20 
min at 37ºC as described below [49]. 
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 Buffer 2-PAM 
Control - 1 1 µL  
Control - 2 1 µL  
Control - 3 - 1 µL 
   
Sample -1  - 0.5 µL 
Sample -2 - 1 µL 
   
After oxime treatment, the sample and control activity was challenged by the addition of 
1 µg of ACTH 1-39 for 6 h at 37ºC [46].  Additionally, an ACTH 1-39 blank sample was 
prepared by adding 100 µL assay buffer, 1 µL ACN, and 1 µL ACTH 1-39 to the 37ºC 
incubator for 6 h.  The reactions were quenched by the addition of 10 µL of 10%TFA 
(aq) [44]. 
 Solutions were spotted on a weak-cation exchange protein chip as described for 
the PC1/3 activity assay.  Spotted samples were analyzed for PC2 processing products, 
ACTH 1-17 and ACTH 18-39, in reflected positive ion mode on the Bruker AutoFlex III 
MALDI-TOF MS utilizing an external calibration method.  Laser intensity was set at 
15% and the acceleration voltage was 20kV. Approximately 50 spectra, 200 laser shots 
each, were taken.  The baselines were subtracted and the relative intensities, processing 
peak intensity vs. ACTH 1- 39 peak intensity, were calculated.  The relative intensities 
were put in numerical order and the six spectra from each sample preparation with the 
closest relatative intensities were saved, analyzed and graphed [47].  Utilizing the Prism 
Graph Pad Software, an unpaired student’s t-test was used to determine if the means of 
the relative intensities of each treatment group were statistically significant (p <0.05) 
when compared to the positive and negative controls.  Additionally, any reactivation by 
oxime treatment will be determined by the following equation [49]. 
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RESULTS 
ENDOPROTEASE DIGESTION OF PROHORMONE CONVERTASE 1/3  
 The enzymatic digestion of PC1/3 yielded only three peaks greater than 500 Da.  
These peaks were observed at 1077 Da, 1349 Da, and 2652 Da (Figure 7).  The three 
peaks were only observed in the control, ACN treated, sample.  Additionally, peaks did 
not correspond to any theoretical peptides which should be produced by a digestion with 
endoproteinase Glu-C.  Therefore, no MASCOT search was completed and no results 
were obtained. 
 
ENDOPROTEASE DIGESTION OF PROHORMONE CONVERTASE 2 
 The enzymatic digestion of PC2 yielded 15 MS peaks, in each of the control and 
CHP-O challenged sample, which corresponded to theoretical cleavages made by an 
endoprotienase Glu-C digestion with PC2 (Figures 8 and 10).  Of the 15 corresponding 
peaks, 12 of those were observed in both the control and challenged sample.  
Additionally, both control and CHP-O challenged sample retrieved a highly significant 
match for homologous masses in the MASCOT server (p <0.05) (Figures 9 and 11).  
Furthermore, the digestion resulted in sequence coverage of 30% in the control and 25% 
in the CHP-O challenged sample (Figures 9 and 11).  However, none of the peaks 
observed in the experiment correspond to a peptide containing the active site serine 
(Figures 9 and 11).   
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 Figure 7:  Mass spectra of the endoproteinase Glu-C digestion of PC1/3.  A) Mass 
spectra of the control sample, ACN treatment.  B) Mass spectra of the CHP-O treated 
sample.
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Figure 8:  Mass spectra of the PC2 control sample digest by endoproteinase Glu-C.  
Labeled peaks correspond to the peptides made by the theoretical cleavages of Glu-C.  
The inset spectra is the area where the peak corresponding to the peptide containing the 
active site serine should be located. Mass spectra were captured on the MALDI-TOF MS 
in reflective positive ion mode by adding 1200 laser shots at 15% laser intensity with an 
acceleration voltage of 20kV.
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Figure 9:  MASCOT server search for homologous peptide masses from the PC2 control 
sample digest by endoproteinase Glu-C (Figure 8).  30% sequence coverage was 
displayed for this digest.  A significant match, score >70 = p <0.05, for PC2 was 
observed.  However, the peptide containing the active site serine at 384aa was not found.
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 Figure 10:  Mass spectra of the PC2 CHP-O challenged sample digest by endoproteinase 
Glu-C.  Labeled peaks correspond to the peptides made by the theoretical cleavages of 
Glu-C.  The inset spectra is the area where the peak corresponding to the peptide 
containing the active site serine, if phosphorylated, should be located. Mass spectra were 
captured on the MALDI-TOF MS in reflective positive ion mode by adding 1200 laser 
shots at 15% laser intensity and 20kV acceleration voltage.
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Figure 11:  MASCOT server search for homologous peptide masses from the PC2 CHP-
O challenged sample digest by endoproteinase Glu-C (Figure 10).  25% sequence 
coverage was displayed for this digest.  A significant match, score >70 = p <0.05, for 
PC2 was observed.  However, the peptide containing the active site serine at 384aa was 
not found.  Nor were any peaks found corresponding to the active site being 
phosphorylated. 
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PROHORMONE CONVERTASE 1/3 ACTIVITY ASSAY  
 The enzyme activity assay MS for PC1/3 showed significant reduction in the 
processing of ACTH 1-39 into ACTH 1-15 and ACTH 1-17, when pretreated with the 
organophosphate chlorpyrifos-oxon as compared to the vehicle control (p <0.05) (Figures 
12 - 15).  Furthermore, all pretreatment time points, 1 h to 4 h, showed a highly 
significant reduction in processing in comparison to the control sample for both ACTH 1-
15 and ACTH 1-17 (p <0.05).  The 4 h pretreatment time for both doses, 10µM and 
100µM, showed the largest decrease in processing of both ACTH 1-15 and ACTH 1-17.  
 Additionally, the data showed no statistically significant difference between the 
two treatment groups, 10 µM and 100 µM, at any time point for either peptide (p <0.05).  
Furthermore, the 10 µM sample showed no significant difference between the 3 h and 4 h 
pretreatment times for either peptide (p <0.05).  See Appendices 1 and 2 for all MS data 
and peak information. 
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Figure 12:  Representative mass spectra of PC1/3 activity of control and CHP-O 
pretreated samples after 1 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 and ACTH 1-15 peak intensity vs. ACTH 1-39 peak intensity, was 
observed in the CHP-O pretreated samples as compared to the vehicle control.  Mass 
spectra were captured on the MALDI-TOF MS in linear positive ion mode.
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Figure 13:  Representative mass spectra of PC1/3 activity of control and CHP-O 
pretreated samples after 2 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 and ACTH 1-15 peak intensity vs. ACTH 1-39 peak intensity, was 
observed in the CHP-O pretreated samples as compared to the vehicle control.  Mass 
spectra were captured on the MALDI-TOF MS in linear positive ion mode.
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Figure 14:  Representative mass spectra of PC1/3 activity of control and CHP-O 
pretreated samples after 3 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 and ACTH 1-15 peak intensity vs. ACTH 1-39 peak intensity, was 
observed in the CHP-O pretreated samples as compared to the vehicle control.  Mass 
spectra were captured on the MALDI-TOF MS in linear positive ion mode.
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Figure 15:  Representative mass spectra of PC1/3 activity of control and CHP-O 
pretreated samples after 4 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 and ACTH 1-15 peak intensity vs. ACTH 1-39 peak intensity, was 
observed in the CHP-O pretreated samples as compared to the vehicle control.  Mass 
spectra were captured on the MALDI-TOF MS in linear positive ion mode.
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PROHORMONE CONVERTASE 2 ACTIVITY ASSAY 
The resultant MS from the enzyme activity assay of PC2 showed a statistically 
significant decrease in the relative intensity of the product peak, ACTH 1-17, to the 
substrate peak, ACTH 1-39, in the presence of CHP-O pretreatments versus vehicle 
control pretreatment (p <0.05) (Figures 16 - 20).  The significant increase in the ACTH 1-
39 peak intensity in the presence of CHP-O was observed over all pretreatment times, 0.5 
h through 4 h, and across all doses, 10 µM and 100 µM (p <0.05). 
The 0.5 h pretreatment yielded the least reduction in processing (Figure 14, 
Appendices 3 and 4).  Additionally, there was no statistical difference between treatment 
groups, 10 µM and 100 µM, at the 0.5 h and 2 h pretreatment times (p <0.05).  The 100 
µM CHP-O challenged sample showed no statistically significant difference between the 
3 h and 4 h pretreatments (p <0.05).  In contrast, the time point showing the most 
reduction in processing was the 3 h pretreatment time across both treatment groups of the 
oxon, 10 µM and 100 µM.  Interestingly, the 4 h pretreatment time showed a slight 
increase in product when compared to the 3 h pretreatment time.   See Appendices 3 and 
4 for all MS data and peak information. 
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Figure 16:  Representative mass spectra of PC2 activity assay of control and CHP-O 
pretreated samples after 0.5 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 peak intensity vs. ACTH 1-39 peak intensity, was observed in the 
CHP-O pretreated samples as compared to the vehicle control.  Mass spectra were 
captured on the MALDI-TOF MS in reflective positive ion mode.
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Figure 17:  Representative mass spectra of PC2 activity assay of control and CHP-O 
pretreated samples after 1 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 peak intensity vs. ACTH 1-39 peak intensity, was observed in the 
CHP-O pretreated samples as compared to the vehicle control.  Mass spectra were 
captured on the MALDI-TOF MS in reflective positive ion mode.
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Figure 18:  Representative mass spectra of PC2 activity assay of control and CHP-O 
pretreated samples after 2 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 peak intensity vs. ACTH 1-39 peak intensity, was observed in the 
CHP-O pretreated samples as compared to the vehicle control.  Mass spectra were 
captured on the MALDI-TOF MS in reflective positive ion mode.
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Figure 19:  Representative mass spectra of PC2 activity assay of control and CHP-O 
pretreated samples after 3 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 peak intensity vs. ACTH 1-39 peak intensity, was observed in the 
CHP-O pretreated samples as compared to the vehicle control.  Mass spectra were 
captured on the MALDI-TOF MS in reflective positive ion mode.
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Figure 20:  Representative mass spectra of PC2 activity assay of control and CHP-O 
pretreated samples after 4 h pretreatment.  A) Vehicle control pretreatment. B) 10 µM 
pretreatment. C) 100 µM pretreatment.  A significant decrease (p <0.05) in the relative 
intensity, ACTH 1-17 peak intensity vs. ACTH 1-39 peak intensity, was observed in the 
CHP-O pretreated samples as compared to the vehicle control.  Mass spectra were 
captured on the MALDI-TOF MS in reflective positive ion mode. 
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PC2 ACTIVITY ASSAY WITH OXIME TREATMENT 
The resultant MS from the enzyme activity assay of PC2 with an oxime (2-PAM) 
treatment showed a statistically significant reactivation of PC2 processing capabilities of 
ACTH 1-39 in vitro (p <0.05) (Figures 21 and 22).  Although reactivation was 
statistically significant from that of the negative control (Control 2), it was statistically 
significant from of the positive control as well (Control 1) (p <0.05).  Additionally, the 
two oxime treatments tested, 50 µM and 100 µM, were statistically significant from each 
other (p <0.05).  Furthermore, no statistical difference was observed in the comparison 
between the positive control, Control 1, and the oxime control, Control 3.  Conversely, 
statistical significance was demonstrated between positive control, Control 1, and 
negative control, Control 2 (p <0.05).  In addition by utilizing the equation from the work 
of  Kuca et.al., a 57.2% and 59.5% reactivation was demonstrated for the 50 µM and the 
100 µM oxime treatment [49]. 
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 Figure 21:  Representative mass spectra of PC2/oxime activity assay of control samples 
1 - 3.  A) Control 1, no CHP-O or oxime B) Control 2, CHP-O treatment, no oxime C) 
Control 3, no CHP-O, oxime treatment  A significant decrease in the relative intensity (p 
<0.05), ACTH 1-17 peak intensity vs. ACTH 1-39 peak intensity, was observed in the 
CHP-O pretreated sample, control 2, as compared to the vehicle control, control 1. 
Additionally, no statistically significance was shown between control 1 and control 3.  
Mass spectra were captured on the MALDI-TOF MS in reflective positive ion mode.
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Figure 22:  Representative mass spectra of PC2/oxime activity assay of oxime treated 
samples 1 and 2.  A) Sample 1, 50 µM oxime treatment B) Sample 2, 100 µM oxime 
treatment.  A significant increase in the relative intensity (p <0.05), ACTH 1-17 peak 
intensity vs. ACTH 1-39 peak intensity, was observed in the oxime pretreated samples, 
samples 1 and 2, as compared to the vehicle control, control 1, and CHP-O control, 
control 2. Additionally, the two sample treatments were statistically significant from each 
other.  Mass spectra were captured on the MALDI-TOF MS in reflective positive ion 
mode.
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DISCUSSION 
MALDI-TOF MASS SPECTROMETRY – ENDOPROTEASE DIGESTION 
The MALDI-TOF MS is a highly sensitive and fairly robust instrument.  Most 
MALDI-TOF instruments can detect down to the picamole levels with high accuracy and 
resolution [42].  Additionally, the ability to detect and identify proteins in complex 
biological mixtures with little preparation has allowed for great advances in many aspects 
of biology [42].  Furthermore, the capability to detect post-translational modifications 
(PTM) and the amino acid to which the modification is made has allowed for further 
understanding of intracellular signaling and signal transduction [42].  In addition to 
native PTMs, modifications by various chemicals can also be analyzed by MALDI-MS 
[42]. 
Detection of phosphorylation by organophosphate compounds to various 
biological molecules has been conducted to varying degrees [40, 41, 49].  However, 
direct analysis of a bulky biological molecule, like an enzyme, for PTMs is difficult.  The 
high laser energy required to ionize an intact large molecule in conjunction with the large 
quantities necessary to yield a quality response result in a broad poorly resolved peak 
(Figure 23) [42].  It is difficult to observe a peak shift of less than 100 Da from these 
broad peaks.  Therefore, endoproteolytic digestion is a necessary alternative for the 
observation of PTMs by MALDI-MS [42].  The smaller protein fragments can easily be 
resolved to show the fragment ions and PTMs (Figure 23) [42].  PTMs can be observed 
by a shift in mass of a fragment corresponding to the appropriate mass of the PTM 
binding [42].  If there is sufficient ion abundance, further fragmentation by collision-
induced-disassociation (CID) or post-source decay (PSD) can be conducted to  
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Figure 23:  Pictorial representation of common MALDI MS analysis.  Mass spectra of 
the intact protein (left) can be determined which will yield a large broad peak.  
Proteolytic digestion will yield peptide fragments which will commonly yield narrow 
highly resolved peaks (middle).  Further fragmentation of a single peptide from the 
proteolytic digestion can be made by breaking the peptide down into its amino acid ions 
[42]. 
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determine the specific amino acid to which the PTM was made (Figure 23) [42].  This 
analysis for location of PTMs in the amino acid sequence was not available before 
advancements in MS [42]. 
 Identification of protein identity and any PTMs are commonly done by searching 
a protein database.  This study made use of the MASCOT data base.  However, there are 
several other databases commercially available [42].  It is generally accepted that all the 
protein databases work in the same fashion [42].  Each takes the intact protein and applies 
the theoretical cleavage points of a proteolytic enzyme to that protein [42].  This reveals 
the theoretical peptides made by the enzyme from the protein (Figure 24) [42].  Using the 
theoretical mass of each amino acid, each peptide mass can be calculated (Figure 24) 
[42].  The data base compares the calculated peptide mass vs. the observed experimental 
mass from the mass spectrum and assigns it a score based on their relationship (Figure 
24) [42].  The corresponding score also takes into account the probability of obtaining the 
peptides randomly or from another protein [42].  Therefore, statistical significance can be 
assigned to the protein identification [42].   
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Figure 24:  Pictorial representation of protein database scoring.  On the left is the 
experimental method utilizing an endoproteolytic digestion and mass spectrometry to 
identify the peptide fragments from the digestion.  On the right is the method for 
determining the theoretical cleavage points and subsequent masses from a digestion of a 
known protein.  The two methods are compared and assigned a score based on their 
relationship [42]. 
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ENDOPROTEASE DIGESTION OF CARBOXYLESTERASE 
The MALDI-TOF MS was purchased and installed as the first of its kind at 
Wright State University in January of 2008.  Due to this fact, no working protocols 
existed for the direct analysis of a proteolytic digestion of a natural substance for use with 
the MALDI-TOF MS.   Therefore, sufficient method development had to be conducted to 
develop a functional enzymatic digestion.  To begin, large quantities of carboxylesterase 
(Sus Scrofa) existed in the Cool lab from previous experiments.  Casida et.al. has 
referenced that carboxylesterase is sensitive to inhibition by chlorpyrifos-oxon [28].  As a 
result, method development of the endoproteolytic digestion was conducted with 
carboxylesterase from the Sus Scrofa. 
In brief, many aspects of the method were changed and subsequently analyzed for 
the quality of mass spectra produced and quantity of the resultant fragmentation.  For 
example, the carboxylesterase concentration, the use of various endoproteases, 
endoprotease concentration, volume of buffer, time allowed for digestion, various protein 
denaturants, variable concentrations of the solutions used in the zip-tipping process, type 
of zip-tip, type of matrix used, additives to the matrix, and solution concentration of the 
matrix were all evaluated to produce the optimum digestion and spectra for the protein 
(data not shown).  The method reflected in the materials and method section is the result 
of the method development. 
Sufficient difficulties exist for positive ionization of phosphorylated peptides due 
to the high electronegativity of the phosphorous atom [19, 51].  Sun et.al. reported that 
the addition of diammonium citrate to the matrix/sample solution increases the ionization 
of the phosphopeptide to detectable levels by working as an electron scavenger [42, 51].  
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Otherwise, detection of phosphopeptides can be extremely sparse, although possible as 
referenced by Elhanay et.al., Jennings et.al. and Sun et.al [40, 41, 51].  Conversely, 
negative ionization methods were not explored due to the small amount of material found 
on the subject when searched. 
Additionally, reducing the disulfide bonds and alkylating the cysteines on the 
target enzyme did not show a significant difference in the production of the active site 
peptide of carboxylesterase.  Therefore, this step was eliminated from the experiment.  
However, each digestion is not alike as reported by Medzihradszky [58].  Consequently, 
the conditions which are appropriate for the digestion of carboxylesterase may not be the 
case for the PC enzymes [52].  As a result, what is reflected in the materials and methods 
section is what “worked” for the PC enzymes not necessarily what “worked” for 
carboxylesterase.    
To further investigate the digestion, different concentrations of carboxylesterase 
versus concentration of endoprotease were evaluated.  Various reports show that 
anywhere from 1:20 thru 1:100 endoprotease to target protein can be used [40, 41].  
Increasing the concentration of the endoprotease did not significantly affect the amount 
of carboxylesterase peaks.  However, no adverse effects were demonstrated by the 
addition of a higher concentration of endoprotease.  Furthermore, this work demonstrated 
that to observe a significant match in the MASCOT server for homologous fragments, a 
minimum of 5 µg of carboxylesterase was needed.  The addition of 10µg showed the 
greatest digestion but no difference between 10 µg and 15 µg was observed (data not 
shown).     
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Moreover, the endoproteases themselves are susceptible to phosphorylation by 
OP’s. With trypsin and Glu-C, diisoflorophosphate inhibits the endoprotease rendering it 
ineffective [53].  Sufficient work was completed to try to remove the OP from the 
experiment by centrifuge filtering the enzyme out by molecular weight.  However, 
recovery of the target enzyme after filtration was inconsistent and led to unpredictable 
digestion afterward although manufacturer claimed >95% recovery.  Therefore, the OP 
could interact with the target enzyme and the endoprotease throughout the entire 
experiment.  
The mass spectra shown in Figures 25 and 27 are examples of the mass spectra 
resulting from a proteolytic digestion of carboxylesterase utilizing endoprotienase Glu-C.  
The mass shift observed in Figure 27 is the expected shift by the binding of aged 
chlorpyrifos-oxon, 92 Da, to the active site peptide of carboxylesterase.  The peptide 
fragment showing the mass shift was not in sufficient abundance to allow for further 
fragmentation.  Therefore, it is only assumed the mass shift is due to binding with the 
active site serine because confirmation by CID was impossible.   
In addition, sufficient digestive fragments of carboxylesterase exist in the peptide 
mass fingerprint to allow for significant positive identification (score >70 = p <0.05) 
when searched for homologous sequences in the MASCOT server (Figures 26 and 28).  
42%, control, and 36%, challenge, of the carboxylesterase (Sus Scrofa) sequence was 
matched for the digestion (Figure 26 and 28).  These results demonstrate that the method 
can detect the phosphorylated peptide fragment and subsequent mass shift when 
compared to the control fragment.   
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Figure 25:  Mass spectra of the carboxylesterase (Sus Scrofa) control sample digest by 
endoproteinase Glu-C.  Labeled peaks correspond to the peptides made by the theoretical 
cleavages of Glu-C.  The inset spectra is the peak corresponding to the peptide containing 
the active site serine. 
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Figure 26:  MASCOT server search for homologous peptide masses from the 
carboxylesterase (Sus Scrofa) control sample digest by endoproteinase Glu-C (Figure 25).  
42% sequence coverage was displayed for this digest including the peptide containing the 
active site serine at 221aa.  Also a significant match, score >70 = p <0.05, for 
carboxylesterase was observed.
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Figure 27: Mass spectra of the carboxylesterase (Sus Scrofa) CHP-O challenged sample 
digest by endoproteinase Glu-C.  Labeled peaks correspond to the peptides made by the 
theoretical cleavages of Glu-C.  The inset spectra is the peak corresponding to the peptide 
containing the active site serine.  A mass shift of 92Da was observed in the active site 
containing peptide.  The mass shift observed would correspond to an aged CHP-O 
molecule attachment.
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Figure 28: MASCOT server search for homologous peptide masses from the 
carboxylesterase (Sus Scrofa) CHP-O challenged sample digest by endoproteinase Glu-C 
(Figure 27).  36% sequence coverage was displayed for this digest including the peptide 
containing the active site serine at 221aa.  The mass shift corresponding to aged CHP-O 
to the active site peptide is recognized in the search.  Also a significant match, score >70 
= p <0.05, for carboxylesterase was observed. 
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ENDOPROTEASE DIGESTION OF PROHORMONE CONVERTASE 1/3 
 The endoprotease digestion of PC1/3 yielded only three peaks at 1077 Da, 1349 
Da, and 2652 Da (Figure 7).  These masses did not correspond to any theoretical 
cleavages of PC1/3 by endoproteinase Glu-C (Table 1).  Many factors or a combination 
of factors could be responsible for the lack in presence of peaks from this digestion. 
 First and foremost, as described above, sufficient work had been completed to use 
molecular weight centrifuge filters to remove the OP after treatment.  Recovery of the 
target protein had been sporadic at best contrary to the manufacturer’s claims.  However, 
this method was used in spite of the previous results due to the hydrophobic nature of 
CHP-O [54].  The previous work with carboxylesterase was done at significantly lower 
concentrations of CHP-O than that used for the PC1/3 digestion.  Higher concentrations 
of CHP-O were used to observe the maximum amount of inhibition in the CHP-O treated 
sample therefore increasing the probability of observing a mass shift.  This increase 
caused the CHP-O to precipitate when spotted on the ground steel chip. The resultant 
precipitated solution showed no response when analyzed.  Therefore, the molecular 
weight filter was used to try to remove the CHP-O from the solution to suppress the 
tendency for precipitation. 
 Additionally, several other factors could account for the poor digestion.  The 
endoproteinase was aliquotted and frozen for a substantial length of time.  There could  
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Table 1:  Theoretical cleavages of PC1/3 made by enzymatic digestion with 
endoproteinase Glu-C in an ammonium bicarbonate buffer at pH 7.8.  The active site 
serine is located at amino acid 382.  The accepted values are calculated based upon 
the theoretical molecular weight of the amino acids contained in that peptide by 
cleavage on the C-terminal side of glutamic acid residues. 
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have been a significant loss in enzymatic activity based on the freezing and thawing 
cycle. This could have lead to a lack in production of peptides or a smaller abundance of 
peptides being produced.   
Furthermore as stated above, Medzihradszky reported that digestive conditions 
required for one target protein are not necessarily the same for another [52].  Therefore, 
PC1/3 may require denaturing for a large abundance of protein to be digested.  The PC1/3 
digestion was not denatured based on results from the carboxylesterase digestion.  Maybe 
it was necessary.  However, a lack in quantity of PC1/3 available for use limited 
proceeding with another digestion. 
A single factor, or a combination of factors lead to the failure in the PC1/3 
digestion.  From this digestion, it is inconclusive as to whether the active site serine of 
PC1/3 is phosphorylated by the CHP-O molecule.  However with a few slight method 
variations and an abundance of PC1/3 in which to work with, phosphorylation of the 
active site serine could be shown for PC1/3 if it exists. 
 
ENDOPROTEASE DIGESTION OF PROHORMONE CONVERTASE PC2 
 The endoprotease digestion of PC2 produced mixed results.  The digest resulted 
in a large quantity of peaks (Figures 8 and 10).  However only a handful of those 
produced, correlated to theoretical cleavages of PC2 by Glu-C (Figures 9 and 11, Table 
2).  While those peaks were enough to result in a significant match (p <0.05) of  
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Table 2:  Theoretical cleavages of PC2 made by enzymatic digestion with 
endoproteinase Glu-C in an ammonium bicarbonate buffer at pH 7.8.  The active site 
serine is located at amino acid 384.  The accepted values are calculated based upon 
the theoretical molecular weight of the amino acids contained in that peptide by 
cleavage on the C-terminal side of glutamic acid residues.   
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homologous masses in the MASCOT server for PC2, the active site serine peptide was 
not present in either the control or challenge sample (Figures 9 and 11).  
These results are not unanticipated.  In the previous work conducted with 
carboxylesterase, sufficient difficulty was observed in getting the active site peptide to 
become detected when sufficient peaks exist to produce a match in the MASCOT search.  
It is unknown what the cause of this difficulty stems from.  Like the PC1/3 reaction, it 
could be a host of problems from digestion problems to MALDI-TOF problems.   
Unlike PC1/3, the PC2 digestion produced peptide peaks corresponding to PC2, 
therefore eliminating the cause attributed to degradation of the endoprotienase Glu-C.  
However, endoprotienase Glu-C is reported to cleave the C-terminal side of a protein at 
glutamic acid residues in an ammonium bicarbonate buffer at pH 7.8.  These were the 
conditions which the PC2 digestion was conducted.  However, it is also reported that 
Glu-C will cleave at the C-terminal side of aspartic acid residues in addition to glutamic 
acid residues in the presence of a phosphate buffer at pH 4.0.  The peaks observed and 
matched in the MASCOT server in the PC2 experiment corresponded to cleavage at both 
aspartic acid and glutamic acid residues.  Therefore, it would seem as though the 
endoprotienase Glu-C had lost some of its specificity.  This would also explain the 
abundance of “random” peaks not associated with any theoretical cleavages of PC2 
(Figures 8 and 10).  Furthermore, it is entirely possible that one of these “random” peaks 
contains the active site serine but went undetected due to the loss in the specificity and 
the predictability of Glu-C.   
Additionally, based on the matches observed in the MASCOT search for 
homologous masses, only the C-terminal end of PC2 was digested with any abundance 
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(Figures 9 and 11).  Therefore, it is unknown if the peptides for the N-terminal of PC2 
were produced and not detected or not produced at all.  Increasing the digestion time 
could possibly produce the N-terminal peptides.  However, it has been reported that 
lengthy digestion times cause an increase in non-specific cleavages [52].  Therefore, 
increasing the digestion length was not explored. 
In addition, based on experimentation with carboxylesterase, it has been observed 
as peptide fragments increase in molecular weight it becomes sufficiently more difficult 
to detect their presence in the reflective mode.  The endoprotienase Glu-C was selected 
for the experiment because it would theoretically cleave the active site serine of PC2 into 
a peptide of approximately 2462 Da (Table 2).  However, if Glu-C were to miss a 
cleavage point, or several points, the peptides produced could be larger than 3700 Da, the 
approximate size of the largest peptide detected in reflective mode in previous 
experimentation, and therefore go undetected.  This is believed to be caused by 
suppressed ionization of the larger peptides [42].  Therefore, the active site serine peptide 
could be present from the digestion but go undetected due to ion suppression.   
A single factor or a combination of factors could have lead to the lack in detection 
of the active site serine peptide from the PC2 digestion.  From this digestion, it is 
inconclusive as to whether the active site serine of PC2 is phosphorylated by the CHP-O 
molecule.  However, significant matches for homologous masses in the MASCOT server 
were observed in both the PC2 control and CHP-O challenged sample.  Therefore, this 
digestion, with a few slight alterations, could potentially produce the active site serine 
peptide and possibly a mass shift corresponding to phosphorylation.  However, only a 
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small quantity of PC2 currently existed for this study and more would have to be 
harvested prior to any further work. 
 
MALDI-TOF MASS SPECTROMETRY – ENZYME ACTIVITY ASSAY 
 The MALDI-TOF instrument is ideal for use to monitor enzyme activity and 
parallel enzyme inhibitor assays [47].  MALDI-TOF MS allows for the direct analysis of 
the native substrate and subsequent products produced [47].  Because of this quality, the 
MALDI analysis removes the tendency that the common fluorescence assays to give false 
positive or false negative results [47].  Therefore, the use of MALDI MS gives a more 
accurate result and removes the need to purchase expensive fluorescent chemicals [47].   
 In MALDI MS, comparison of the relative intensities of the observed peaks to 
each other, within a spectrum, should allow for a semi-quantitative method without the 
use of an internal standard.  The semi-quantitative nature of the method stems from the 
lack in homogeneity of the matrix-analyte solution, or in this case the irregular binding of 
substrate and product across the Protein Chip array, and subsequent crystallization [47].  
Therefore, the shot-to-shot and spot-to-spot intensities of peaks across a sample spot can 
vary [47].   
 In the enzyme activity assay described above, the inconsistency in the response 
from each set of laser shots at different locations on the sample spot was resolved by 
randomly taking approximately 50 laser shots across the sample spot.  The baseline was 
subtracted from each spectra and the relative intensities were calculated.   The relative 
intensities were placed in numerical order and the six closest relative intensities were 
considered representative of the entire sample spot.  These six spectra were saved, the 
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relative intensites were plotted, the replicates were overlaid and averaged.  This method 
should account for any fluxuation in the response across the sample spot.  The average of 
each sample’s relative intensities should allow for statistical comparison of the averages 
between vehicle control and the sample treatments.  Therefore, this was the method used 
for description of the activity of PC1/3 and PC2’s processing of ACTH 1-39.  
  
PROHORMONE CONVERTASE 1/3 ACTIVITY ASSAY 
The enzyme activity assay of PC1/3 demonstrated a significant reduction in the 
production of ACTH 1-15 and ACTH 1-17 when in the presence of a CHP-O 
pretreatment across micro molar concentrations when compared to vehicle control (p 
<0.05) (Figures 29 - 33).  Additionally, this observation was true across all, 1 h to 4 h, 
pretreatment times when compared to control (Figure 33).  The results observed suggest 
that CHP-O pretreatment reduces the processing capabilities of PC1/3 in vitro. 
Furthermore, there was no significant observed difference between treatment 
groups, 10 µM and 100 µM, across all time points for both peptides, ACTH 1-15 or 
ACTH 1-17.  This suggests that the lower limit of CHP-O concentration necessary to 
show inhibition would be below 10 µM.  However, the doses tested were not selected to 
show the minimum concentration for inhibition.  The 10 µM and 100 µM concentrations 
were selected based on Hreljac et.al’s suggestion to use these doses to mimic 
environmental and acute exposures in human in vivo studies [45].   
Additionally, the 10 µM sample did not show a significant difference between the 
3 h and 4 h pretreatment time for either peptide, ACTH 1-15 or ACTH 1-17.  These 
results would suggest that at 3 h the maximal inhibition had taken place for the 10 µM  
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Figure 29: Plot of the relative intensities, ACTH 1-15 and ACTH 1-17 peak intensity to 
ACTH 1-39 peak intensity, for each mass spectra after 1 h CHP-O pretreatment (See 
Figure 12 and Appendix 3 & 4 for MS and data summary). Closed points correspond to 
the 6 replicate 1 mass spectra and opened points correspond to the 6 replicate 2 mass 
spectra.  * represents statistical significance between means (line) of each treatment 
group when compared to the mean of the vehicle group by a students t-test, p < 0.05.
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Figure 30: Plot of the relative intensities, ACTH 1-15 and ACTH 1-17 peak intensity to 
ACTH 1-39 peak intensity, for each mass spectra after 2 h CHP-O pretreatment (See 
Figure 12 and Appendix 3 & 4 for MS and data summary). Closed points correspond to 
the 6 replicate 1 mass spectra and opened points correspond to the 6 replicate 2 mass 
spectra.  * represents statistical significance between means (line) of each treatment 
group when compared to the mean of the vehicle group by a students t-test, p < 0.05.
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Figure 31: Plot of the relative intensities, ACTH 1-15 and ACTH 1-17 peak intensity to 
ACTH 1-39 peak intensity, for each mass spectra after 3 h CHP-O pretreatment (See 
Figure 12 and Appendix 3 & 4 for MS and data summary). Closed points correspond to 
the 6 replicate 1 mass spectra and opened points correspond to the 6 replicate 2 mass 
spectra.  * represents statistical significance between means (line) of each treatment 
group when compared to the mean of the vehicle group by a students t-test, p < 0.05.
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 Figure 32: Plot of the relative intensities, ACTH 1-15 and ACTH 1-17 peak intensity to 
ACTH 1-39 peak intensity, for each mass spectra after 4 h CHP-O pretreatment (See 
Figure 12 and Appendix 3 & 4 for MS and data summary). Closed points correspond to 
the 6 replicate 1 mass spectra and opened points correspond to the 6 replicate 2 mass 
spectra.  * represents statistical significance between means (line) of each treatment 
group when compared to the mean of the vehicle group by a students t-test, p < 0.05.
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Figure 33:  A plot of the mean of each set of relative intensities from the PC1/3 activity 
assay, mean of all points from figures 29 - 32, across all time points.  The blue (ACTH 1-
17) and grey (ACTH 1-15) lines and points represent the vehicle control mean relative 
intensities.  The green (ACTH 1-17) line and points represent the 10µM CHP-O 
pretreatment dose mean relative intensities.  The red (ACTH 1-17) line and points 
represent the 100µM CHP-O pretreatment does mean relative intensities. The orange 
(ACTH 1-15) line and points represent the 10 µM CHP-O pretreatment dose mean 
relative intensities.  The purple (ACTH 1-15) line and points represent the 100 µM CHP-
O pretreatment does mean relative intensities.   All data points are statistically significant 
(p <0.05) when compared to the control values. 
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dose.  This could arise from all the CHP-O reacting leaving no more remaining to further 
inhibit the excess of enzyme present.  This is further strengthened by the 100 µM sample 
showing a further decrease in processing between the three and four hour pretreatment 
times.   All other sample treatments showed significant differences between pretreatment 
times (p <0.05). 
The observed peaks in the all the spectra were not exceedingly intense for ACTH 
1-15 or ACTH 1-17.  Furthermore, ACTH 1-39 was not nearly processed to completion 
(Figures 29 - 32).  Processing of ACTH 1-39 by PC1/3 was expected to be small [44].  
However based on the work of Friedman et.al., processing was anticipated to be greater 
than what was observed based on the high sensitivity of MALDI-MS.  Their research, 
and others, determined that the main processing locations for PC1/3 are at the KR sites of 
POMC for liberation of ACTH and β-lipotropin rather than cleaving ACTH into smaller 
peptides [44].  However, they also determined that there is a minor cleavage by PC1/3 at 
the KKRR site inside ACTH at 16 h incubation [44].  Thus, ACTH 1-39 was used as the 
substrate in the assay. 
The peaks associated with ACTH 1-39, ACTH 1-15, and ACTH 1-17 were not 
the only peaks to be observed in the experiment.  Although the rhPC1/3 was purchased 
from R&D Systems with a claimed purity of greater than 95%, contamination processing 
peaks of the ACTH 1-39 substrate were observed.  Based on previously published work, 
the contaminant is thought to be carboxypeptidase [30, 44, 55].  This is due to the 
observance of peaks, which correspond to the removal of one amino acid from the C-
terminal of the substrate (Figures 29 - 32) [55]. The carboxypeptidase, although in a 
quantity less than 5% the total quantity, had a much higher activity toward ACTH 1-39 
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than PC1/3.  The presence of this contaminant in the experiment are biologically founded 
as well.  Carboxypeptidase is secreted with the PC enzymes to cleave the C-terminal 
lysine or arginine from the peptide after cleavage by the PC enzymes [30]. 
To minimize the effect of the contaminant on the experiment, the pH of the buffer 
was lowered from 6.0 to approximately pH 5.  The adjustment in pH was made to attempt 
to suppress the effects of carboxypeptidase, moving away from its pH optimum, while 
retaining the most PC1/3 activity possible.  This could have two potential effects on the 
data.  First, a potential reduction in contamination peaks due to adjustment in pH.  
Second, a reduction in PC1/3 activity based on the work by Friedman in determining pH 
optimum is 6.0 for this assay [44].   
Additionally, the incubation time was shortened in an effort to keep the 
carboxypeptidase from processing ACTH 1-39 down to the ACTH 1-15 and ACTH 1-17 
range.  However in doing so, PC1/3 did not have adequate time to process ACTH 1-39 in 
any sufficient quantity although enough was processed to be detected by MALDI-MS 
[44].  If MS had not been used, the peaks and observations made would not have been 
seen by fluorescence or processing by PC1/3 could have been mistaken for 
carboxypeptidase activity.   
The results in this study are inconclusive for the processing of ACTH 1-39 by 
PC1/3 demonstrated by Friedman et.al. by mass spectrometric methods due to 
contamination of the rhPC1/3 [44].  However, peaks were observed at about 1807 Da and 
2092 Da corresponding to ACTH 1-15 and ACTH 1-17 in great enough abundance to see 
a reduction in relative intensity in the presence of CHP-O when compared to vehicle 
control.  However, whether the observance of the peaks at 1807 Da and 2092 Da were a 
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result of PC1/3 alone or carboxypeptidase alone or a combination of both cannot be 
determined from this assay.  Since the distinction between the two enzymes cannot be 
made, this assay suggests that the processing of ACTH 1-39 by PC1/3 and 
carboxypeptidase are both reduced in the presence of CHP-O over various pretreatment 
times.  This is plausible because carboxypeptidase is also a serine hydrolase which could 
be susceptible to CHP-O. 
 
PROHORMONE CONVERTASE 2 ACTIVITY ASSAY 
 The enzyme activity assay for the processing of ACTH 1-39 by PC2 showed 
significant reduction in the production of ACTH 1-17 in the presence of CHP-O when 
compared to vehicle control across all pretreatment times (p <0.05) (Figures 34 - 39).  
Additionally, the 0.5 h and the 2 h pretreatment times showed no significant difference 
between the treatment doses, 10 µM and 100 µM.   
Furthermore, the 100 µM dose showed no significant difference between the 3 h 
and 4 h pretreatment times.  These results would suggest that maximal inhibition of the 
PC2 enzyme was achieved at a 3 h pretreatment time at 100 µM CHP-O.  Additionally, a 
slight increase in processing was observed at the 4 h pretreatment time for both doses.  
This would suggest, what has been reported as, “spontaneous reactivation” of the enzyme 
by hydrolysis of the phosphor-serine bond [12].   
The processing peak observed at approximately 2092 Da was substantially larger 
than that observed for PC1/3.  This was expected.   It is well documented that PC2 has a 
primary cleavage point for the liberation of α-MSH and CLIP from ACTH [30 – 34, 36].  
It was this peak that was used to determine the activity in the presence of CHP-O. 
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In contrast, no peak was observed for ACTH 18-39 at approximately 2487 Da.  
This was unexpected since there are no additional pairs of dibasic residues for PC2 to  
Figure 34: Plot of the PC2 relative intensities, ACTH 1-17 peak intensity to ACTH 1-39 
peak intensity, for each mass spectra after 0.5 h CHP-O pretreatment (See Figure 12 and 
Appendix 3 & 4 for MS and data summary). Closed points correspond to the 6 replicate 1 
mass spectra and opened points correspond to the 6 replicate 2 mass spectra.  * represents 
statistical significance between means (line) of each treatment group when compared to 
the mean of the vehicle group by a students t-test, p < 0.05.
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Figure 35: Plot of the PC2 relative intensities, ACTH 1-17 peak intensity to ACTH 1-39 
peak intensity, for each mass spectra after 1 h pretreatment (See Figure 13 and Appendix 
3 & 4 for MS and data summary). Closed points correspond to the 6 replicate 1 mass 
spectra and opened points correspond to the 6 replicate 2 mass spectra.  * represents 
statistical significance between means (line) of each treatment group when compared to 
the mean of the vehicle group by a students t-test, p < 0.05.
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Figure 36: Plot of the PC2 relative intensities, ACTH 1-17 peak intensity to ACTH 1-39 
peak intensity, for each mass spectra after 2 h pretreatment (See Figure 14 and Appendix 
3 & 4 for MS and data summary). Closed points correspond to the 6 replicate 1 mass 
spectra and opened points correspond to the 6 replicate 2 mass spectra.  * represents 
statistical significance between means (line) of each treatment group when compared to 
the mean of the vehicle group by a students t-test, p < 0.05.
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Figure 37: Plot of the PC2 relative intensities, ACTH 1-17 peak intensity to ACTH 1-39 
peak intensity, for each mass spectra after 3 h pretreatment (See Figure 15 and Appendix 
3 & 4 for MS and data summary). Closed points correspond to the 6 replicate 1 mass 
spectra and opened points correspond to the 6 replicate 2 mass spectra.  * represents 
statistical significance between means (line) of each treatment group when compared to 
the mean of the vehicle group by a students t-test, p < 0.05.
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Figure 38: Plot of the PC2 relative intensities, ACTH 1-17 peak intensity to ACTH 1-39 
peak intensity, for each mass spectra after 4 h pretreatment (See Figure 16 and Appendix 
3 & 4 for MS and data summary). Closed points correspond to the 6 replicate 1 mass 
spectra and opened points correspond to the 6 replicate 2 mass spectra.  * represents 
statistical significance between means (line) of each treatment group when compared to 
the mean of the vehicle group by a students t-test, p < 0.05.
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Figure 39:  A plot of the mean of each set of relative intensities from the PC2 assay, 
mean of all points from figures 34 - 38, across all time points.  The blue line and points 
represent the vehicle control mean relative intensities.  The green line and points 
represent the 10 µM CHP-O pretreatment dose mean relative intensities.  The red line and 
points represent the 100 µM CHP-O pretreatment does mean relative intensities.  * 
represents statistical significance between the means of each treatment group when 
compared to the mean of the vehicle control group by a students t-test, p < 0.05. 
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further process.  It was expected to observe a peak at 2487 Da with approximately the 
same signal intensity as the 2092 Da peak.  This could be due to ion suppression of 
ACTH 18-39.  However, the absence of the ACTH 1-39 peak does not affect the results 
observed for the ACTH 1-17. 
 
PC2 ACTIVITY ASSAY WITH OXIME TREATMENT  
The oxime treatments, 50 µM and 100 µM, of PC2 following a 100 µM CHP-O 
pretreatment yielded significant reactivation of the inhibited enzyme when compared to 
negative control, Control 2 (Figure 40) (p <0.05).  However, the oxime treated samples 
did not regain full processing capabilities due to the statistical significance shown 
between the positive control, Control 1, and each sample treatment, Sample 1 and Sample 
2.  These results demonstrate that an oxime treatment (2-PAM) at micromolar 
concentrations could potentially reactivate the PC2 enzyme.  
Furthermore, statistical significant reactivation was shown between each oxime 
treatment dose, 50 µM and 100 µM.  These results would suggest higher doses of oxime 
could produce more reactivation.  This observation is supported by the literature [56].  
However, higher doses could go beyond the reasonable treatment doses in vivo. 
Additionally, a 57.2%, 50 µM oxime, and 59.5%, 100 µM oxime, reactivation 
was observed when using the equation from Kuca et.al. [49].  These results are 
approximately 20% higher than that reported for AChE and chlorpyrifos at the same 
oxime dose [49].  This would suggest that 2-PAM has a higher affinity to reactivate PC2 
than AChE in vitro. 
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Figure 40: Plot of the relative intensities, ACTH 1-17 peak intensity to ACTH 1-39 peak 
intensity, for each mass spectra of the oxime reaction (See Figure 16 and Appendix 3 & 4 
for MS and data summary). Closed points correspond to the 6 replicate 1 mass spectra 
and opened points correspond to the 6 replicate 2 mass spectra.  * represents statistical 
significance between means (line) of each treatment group when compared to the mean 
of the vehicle control, control 1, by a student’s t-test, p < 0.05. ** represents statistical 
significance between means (line) of each treatment group when compared to the mean 
of the CHP-O control, control 2, by a student’s t-test, p < 0.05. 
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CONCLUSION 
The direct interactions between chlorpyrifos-oxon, PC1/3 and PC2 were studied 
in vitro.  Mixed results were obtained.  The PC1/3 and PC2 endoproteolytic digestions 
did not yield any peptides corresponding to the peptide containing the active site serine of 
either enzyme.  Furthermore, the PC1/3 digest did not produce any peaks corresponding 
to a Glu-C digestion of PC1/3.  Conversely, the PC2 digestion produced a sufficient 
quantity of peptides to get a significant match for homologous masses in the MASCOT 
server search but as stated above did not produce the active site serine peptide. 
The enzyme activity of PC1/3 and PC2 were challenged in the presence of CHP-
O for the processing of ACTH 1-39 in vitro.  Again, mixed results were obtained.  Both 
the, PC1/3 and PC2, assays resulted in reduction of ACTH 1-39 derived peptides in vitro 
over 1-4 h pretreatment times.  However, contamination of PC1/3 by carboxypeptidase 
did not allow for conclusions about PC1/3 to be directly drawn.  Conversely, the PC2 
activity assay showed a reduction in the processing of ACTH 1-39 and subsequent 
reactivation by oxime treatment in vitro. 
Based on the data presented in this document, it has been shown that there is an 
interaction between CHP-O, PC1/3 and PC2 in vitro.  The extent of the interaction was 
only touched upon with the experiments conducted here.  However based on the data 
presented, further investigation into the interactions of OPs and the Prohormone 
Convertases is warranted. 
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APPENDIX 
Appendix 1:  Mass spectra of the replicate laser shots from PC1/3 enzyme activity assay. 
Blank spectra.  Front 2 spectra: sample with out PC1/3 added.  Rear 2 spectra: sample 
with out ACTH 1-39 added.
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1 h pretreatment:  Blue – Control, Green – 10µM, Red – 100µM.
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2 h pretreatment:  Blue – Control, Green – 10µM, Red – 100µM.
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3 h pretreatment:  Blue – Control, Green – 10µM, Red – 100µM.
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4 h pretreatment:  Blue – Control, Green – 10µM, Red – 100µM.
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Appendix 2: Summary of the mass spectral data from the PC1/3 enzyme activity assay. 
Control - 1hr Pretreatment - Rep 1  10µM - 1hr Pretreatment - Rep 1  100µM - 1hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1813.958 796.757 0.023571  1815.523 424.884 0.015114  1810.375 107.878 0.010916 
2099.317 865.724 0.025612  2103.320 468.310 0.016659  2095.182 156.995 0.015886 1 
4615.609 33801.760 1.000000  
1 
4623.651 28112.215 1.000000  
1 
4610.389 9882.793 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1813.697 677.965 0.023466  1814.347 277.872 0.012001  1810.897 108.000 0.012832 
2099.739 778.859 0.026958  2100.651 360.908 0.015587  2094.199 118.889 0.014125 2 
4616.233 28891.890 1.000000  
2 
4619.988 23154.163 1.000000  
2 
4609.972 8416.624 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1812.980 475.910 0.025370  1813.697 220.688 0.016102  1815.522 298.865 0.013564 
2098.546 479.961 0.025586  2098.196 236.966 0.017290  2100.159 369.479 0.016768 3 
4618.010 18758.848 1.000000  
3 
4616.654 13705.723 1.000000  
3 
4619.472 22034.304 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1815.522 904.920 0.026175  1812.655 279.272 0.012633  1816.175 330.500 0.015341 
2103.248 938.403 0.027143  2098.128 362.878 0.016415  2101.143 338.500 0.015712 4 
4624.802 34572.010 1.000000  
4 
4613.936 22106.317 1.000000  
4 
4619.472 21544.000 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1815.653 737.000 0.027343  1815.458 400.290 0.015146  1816.305 322.980 0.012700 
2101.141 803.091 0.029795  2100.861 460.991 0.017443  2103.318 351.997 0.013841 5 
4619.682 26953.796 1.000000  
5 
4619.785 26428.386 1.000000  
5 
4623.444 25432.211 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1814.284 440.773 0.021772  1814.219 332.903 0.014028  1816.500 348.024 0.014513 
2099.110 522.973 0.025832  2099.738 363.413 0.015313  2102.195 333.430 0.013905 6 
4618.636 20244.949 1.000000  
6 
4620.097 23732.140 1.000000  
6 
4623.127 23979.651 1.000000 
              
Control - 1hr Pretreatment - Rep 2  10µM - 1hr Pretreatment - Rep 2  100µM - 1hr Pretreatment - Rep 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1817.675 353.359 0.024705  1816.565 333.292 0.019083  1816.672 203.953 0.014648 
2105.706 377.997 0.026428  2102.334 289.004 0.016547  2105.344 244.750 0.017578 1 
4626.475 14303.062 1.000000  
1 
4620.938 17465.178 1.000000  
1 
4615.410 13923.957 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1820.807 391.953 0.023415  1816.239 224.956 0.014677  1817.650 328.352 0.016814 
2110.486 419.951 0.025087  2103.458 210.908 0.013761  2105.695 353.870 0.018120 2 
4641.854 16739.698 1.000000  
2 
4621.771 15326.985 1.000000  
2 
4619.266 19528.977 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1819.306 371.947 0.022970  1816.827 325.978 0.017456  1817.716 119.796 0.018133 
2105.847 434.926 0.026859  2102.827 265.668 0.014227  2103.729 118.843 0.017988 3 
4629.189 16193.022 1.000000  
3 
4621.979 18673.985 1.000000  
3 
4620.515 6606.685 1.000000 
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Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1818.261 342.915 0.022006  1812.069 137.982 0.012698  1811.295 114.969 0.012435 
2104.512 413.995 0.026567  2096.513 187.952 0.017296  2096.134 147.937 0.016001 4 
4627.098 15582.927 1.000000  
4 
4614.041 10866.830 1.000000  
4 
4612.585 9245.633 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1818.649 337.321 0.022046  1814.417 471.893 0.016672  1819.503 269.985 0.018838 
2104.442 342.486 0.022384  2099.950 426.991 0.015086  2105.600 238.935 0.016672 5 
4631.180 15300.445 1.000000  
5 
4622.605 28303.879 1.000000  
5 
4632.546 14331.704 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1816.956 783.722 0.025878  1815.718 195.884 0.011479  1819.109 318.440 0.015810 
2103.389 767.762 0.025351  2103.459 218.990 0.012833  2105.743 320.392 0.015907 6 
4625.323 30285.203 1.000000  
6 
4623.855 17064.346 1.000000  
6 
4629.614 20141.472 1.000000 
              
Rel. Intens. Mean - 1807 0.024060  Rel. Intens. Mean - 1807 0.014757  Rel. Intens. Mean - 1807 0.014712 
Rel. Intens. Mean - 2092 0.026205  Rel. Intens. Mean - 2092 0.015966  Rel. Intens. Mean - 2092 0.016054 
 
Control - 2hr Pretreatment - Rep 1  10µM - 2hr Pretreatment - Rep 1  100µM - 2hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1811.621 525.904 0.028044  1816.504 93.998 0.012064  1807.850 167.915 0.011460 
2095.085 504.024 0.026878  2102.092 104.980 0.013473  2091.376 169.742 0.011585 1 
4615.717 18752.601 1.000000  
1 
4626.375 7791.897 1.000000  
1 
4603.298 14652.497 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1811.557 1001.280 0.030203  1817.742 176.917 0.015395  1809.475 101.943 0.010107 
2097.186 915.446 0.027614  2103.214 176.483 0.015357  2093.824 128.978 0.012788 2 
4615.090 33151.463 1.000000  
2 
4625.329 11491.937 1.000000  
2 
4607.992 10085.954 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1811.817 908.987 0.026627  1808.630 89.995 0.011762  1806.420 84.981 0.016056 
2099.077 995.810 0.029170  2094.595 107.946 0.014108  2090.256 76.997 0.014547 3 
4612.168 34137.779 1.000000  
3 
4608.306 7651.470 1.000000  
3 
4601.942 5292.851 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1816.243 230.953 0.024609  1809.280 256.995 0.017665  1806.680 127.953 0.013679 
2107.566 262.922 0.028016  2093.615 219.837 0.015111  2090.816 109.993 0.011759 4 
4625.854 9384.841 1.000000  
4 
4608.411 14548.419 1.000000  
4 
4603.611 9353.986 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1818.459 517.937 0.025219  1806.095 205.498 0.016920  1814.290 185.918 0.012602 
2102.723 570.835 0.027795  2090.814 194.829 0.016041  2100.409 161.997 0.010980 5 
4629.510 20537.336 1.000000  
5 
4603.310 12145.312 1.000000  
5 
4621.149 14753.469 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1810.451 463.642 0.025772  1808.565 251.982 0.018105  1814.290 154.000 0.012543 
2093.824 505.631 0.028106  2092.565 188.169 0.013520  2098.376 180.000 0.014660 6 
4612.793 17990.468 1.000000  
6 
4608.827 13917.825 1.000000  
6 
4618.119 12277.979 1.000000 
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Control - 2hr Pretreatment - Rep 2  10µM - 2hr Pretreatment - Rep 2  100µM - 2hr Pretreatment - Rep 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1816.504 668.961 0.028557  1807.070 128.945 0.013992  1808.694 209.991 0.011798 
2103.495 652.243 0.027843  2092.564 116.917 0.012686  2094.314 224.915 0.012636 1 
4628.467 23425.817 1.000000  
1 
4604.758 9215.916 1.000000  
1 
4607.367 17799.591 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1818.200 487.131 0.022162  1808.695 102.953 0.011333  1809.670 194.990 0.012330 
2105.600 536.936 0.024428  2089.979 110.629 0.012178  2092.984 180.234 0.011397 2 
4628.467 21980.395 1.000000  
2 
4602.986 9084.634 1.000000  
2 
4605.487 15813.779 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1809.150 431.413 0.023391  1810.970 319.778 0.014091  1811.426 245.463 0.013549 
2093.330 488.826 0.026503  2095.855 341.951 0.015068  2095.995 233.980 0.012915 3 
4610.392 18443.888 1.000000  
3 
4609.450 22693.134 1.000000  
3 
4608.096 18116.862 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1809.345 429.978 0.026891  1808.369 265.912 0.015001  1810.579 221.919 0.013681 
2093.124 457.951 0.028641  2091.935 255.987 0.014441  2094.174 213.933 0.013189 4 
4610.393 15989.351 1.000000  
4 
4607.366 17725.955 1.000000  
4 
4609.140 16220.959 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1808.890 382.999 0.025555  1809.020 402.481 0.010924  1814.355 404.000 0.016911 
2092.845 437.738 0.029208  2094.105 467.385 0.012685  2101.321 339.460 0.014209 5 
4609.453 14986.987 1.000000  
5 
4606.636 36844.913 1.000000  
5 
4621.252 23890.205 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1808.826 500.523 0.022950  1809.020 402.465 0.010923  1809.085 169.890 0.011356 
2094.384 623.983 0.028611  2094.104 467.389 0.012685  2092.495 169.999 0.011364 6 
4608.723 21808.869 1.000000  
6 
4606.635 36845.212 1.000000  
6 
4604.863 14959.942 1.000000 
              
Rel. Intens. Mean - 1807 0.025832  Rel. Intens. Mean - 1807 0.014014  Rel. Intens. Mean - 1807 0.013006 
Rel. Intens. Mean - 2092 0.027655  Rel. Intens. Mean - 2092 0.014061  Rel. Intens. Mean - 2092 0.012788 
 
Control - 3hr Pretreatment - Rep 1  10µM - 3hr Pretreatment - Rep 1  100µM - 3hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1812.861 389.940 0.028680  1815.531 78.830 0.009532  1812.860 241.186 0.014138 
2096.888 387.963 0.028534  2098.991 94.956 0.011481  2099.691 203.996 0.011958 1 
4614.576 13596.454 1.000000  
1 
4619.691 8270.360 1.000000  
1 
4617.812 17058.861 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1814.033 453.910 0.027761  1815.206 83.961 0.009777  1810.453 166.815 0.013197 
2100.533 420.492 0.025717  2101.725 80.936 0.009424  2093.876 123.998 0.009810 2 
4618.856 16350.799 1.000000  
2 
4622.825 8587.902 1.000000  
2 
4608.628 12639.933 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1811.819 397.465 0.026803  1815.206 84.999 0.010395  1814.284 91.988 0.013119 
2097.378 394.998 0.026637  2101.515 80.986 0.009904  2099.458 88.995 0.012692 3 
4615.932 14828.991 1.000000  
3 
4622.407 8176.976 1.000000  
3 
4619.890 7011.943 1.000000 
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Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1815.140 382.359 0.029209  1802.393 148.986 0.016301  1813.046 63.981 0.012083 
2101.164 365.933 0.027954  2100.112 101.470 0.011102  2098.967 54.982 0.010384 4 
4624.707 13090.553 1.000000  
4 
4604.247 9139.881 1.000000  
4 
4616.965 5294.999 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1815.597 470.956 0.030071  1808.306 47.995 0.007214  1813.046 156.953 0.015830 
2101.164 459.986 0.029371  2093.315 78.997 0.011874  2097.705 110.997 0.011195 5 
4623.348 15661.476 1.000000  
5 
4587.788 6652.989 1.000000  
5 
4615.399 9915.000 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1814.619 547.972 0.030127  1814.489 173.812 0.015178  1812.916 226.995 0.009899 
2099.902 555.965 0.030567  2100.323 129.910 0.011344  2096.584 259.874 0.011333 6 
4612.697 18188.629 1.000000  
6 
4619.066 11451.457 1.000000  
6 
4613.728 22929.993 1.000000 
              
Control - 3hr Pretreatment - Rep 2    100µM - 3hr Pretreatment - Rep 2 
Shot m/z Intens. Rel. Intens.       Shot m/z Intens. Rel. Intens. 
1815.922 330.637 0.028319      1812.264 266.471 0.010839 
2100.042 341.989 0.029291      2096.933 241.843 0.009837 1 
4623.975 11675.468 1.000000  
 
    
1 
4615.086 24585.444 1.000000 
              
Shot m/z Intens. Rel. Intens.       Shot m/z Intens. Rel. Intens. 
1816.966 389.998 0.023121      1812.264 261.953 0.011400 
2101.515 493.464 0.029255      2097.705 265.961 0.011574 2 
4624.915 16867.754 1.000000  
 
    
2 
4615.296 22978.314 1.000000 
              
Shot m/z Intens. Rel. Intens.       Shot m/z Intens. Rel. Intens. 
1811.103 114.998 0.017990      1813.176 119.949 0.007813 
2095.767 172.986 0.027061      2097.636 151.724 0.009882 3 
4611.758 6392.439 1.000000  
 
    
3 
4617.797 15353.112 1.000000 
              
Shot m/z Intens. Rel. Intens.       Shot m/z Intens. Rel. Intens. 
1824.666 98.988 0.022145      1812.263 77.980 0.008190 
2109.520 125.473 0.028071      2097.495 87.908 0.009233 4 
4643.954 4469.915 1.000000  
 
    
4 
4616.754 9520.938 1.000000 
              
Shot m/z Intens. Rel. Intens.       Shot m/z Intens. Rel. Intens. 
1816.379 97.980 0.025956      1813.958 113.959 0.010307 
2101.796 106.996 0.028344      2100.090 108.396 0.009804 5 
4624.706 3774.916 1.000000  
 
    
5 
4619.470 11056.649 1.000000 
              
Shot m/z Intens. Rel. Intens.       Shot m/z Intens. Rel. Intens. 
1820.944 188.998 0.032738      1814.023 138.645 0.011108 
2107.904 167.737 0.029056      2100.230 147.998 0.011858 6 
4635.267 5772.998 1.000000  
 
    
6 
4621.980 12481.016 1.000000 
              
Rel. Intens. Mean - 1807 0.026910  Rel. Intens. Mean - 1807 0.011399  Rel. Intens. Mean - 1807 0.011494 
Rel. Intens. Mean - 2092 0.028255  Rel. Intens. Mean - 2092 0.010855  Rel. Intens. Mean - 2092 0.010700 
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Control - 4hr Pretreatment - Rep 1  10µM - 4hr Pretreatment - Rep 1  100µM - 4hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1813.957 348.683 0.024546  1814.348 130.925 0.010261  1816.426 133.876 0.011546 
2098.266 414.943 0.029210  2098.477 108.969 0.008541  2102.441 100.980 0.008709 1 
4617.696 14205.496 1.000000  
1 
4617.487 12758.941 1.000000  
1 
4624.739 11594.546 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1814.480 255.988 0.023270  1814.479 105.992 0.009630  1818.248 65.981 0.008332 
2099.038 289.000 0.026270  2099.669 83.407 0.007578  2101.599 71.934 0.009084 2 
4619.680 11000.934 1.000000  
2 
4618.741 11006.675 1.000000  
2 
4625.784 7918.744 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1815.392 586.904 0.025757  1814.805 101.963 0.009597  1817.074 66.951 0.007997 
2101.493 620.492 0.027231  2099.740 74.823 0.007042  2101.740 83.000 0.009914 3 
4617.591 22786.158 1.000000  
3 
4619.472 10624.907 1.000000  
3 
4624.529 8371.858 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1816.892 273.959 0.022887  1814.349 93.948 0.008818  1816.748 55.997 0.009780 
2103.459 325.968 0.027232  2100.160 78.955 0.007411  2102.161 50.969 0.008902 4 
4606.424 11969.915 1.000000  
4 
4620.517 10653.993 1.000000  
4 
4628.397 5725.677 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1813.306 251.999 0.028513  1816.631 119.854 0.013849  1813.228 88.976 0.012109 
2098.827 273.292 0.030923  2100.932 77.962 0.009008  2099.495 65.991 0.008981 5 
4619.784 8837.919 1.000000  
5 
4622.292 8654.551 1.000000  
5 
4619.408 7347.909 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1814.348 358.642 0.024926  1814.936 96.859 0.008743  1815.118 150.999 0.012546 
2099.809 361.469 0.025122  2098.897 84.944 0.007667  2100.547 86.999 0.007228 6 
4620.516 14388.499 1.000000  
6 
4621.144 11078.665 1.000000  
6 
4618.885 12035.916 1.000000 
              
Control - 4hr Pretreatment - Rep 2  10µM - 4hr Pretreatment - Rep 2  100µM - 4hr Pretreatment - Rep 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1815.196 164.987 0.023208  1812.134 92.986 0.010415  1810.559 53.968 0.006938 
2100.090 210.985 0.029679  2096.303 81.998 0.009184  2094.587 69.873 0.008983 1 
4621.771 7108.941 1.000000  
1 
4613.937 8927.894 1.000000  
1 
4611.156 7778.230 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1814.870 184.972 0.019357  1814.610 220.292 0.010579  1814.010 93.955 0.013281 
2100.159 278.940 0.029190  2099.459 197.943 0.009506  2097.812 76.992 0.010883 2 
4601.939 9555.964 1.000000  
2 
4622.189 20823.870 1.000000  
2 
4618.571 7074.523 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1816.826 147.975 0.026931  1815.261 95.992 0.008630  1814.727 180.941 0.015671 
2101.844 169.979 0.030935  2100.862 112.996 0.010158  2101.039 118.990 0.010306 3 
4626.682 5494.688 1.000000  
3 
4620.934 11123.506 1.000000  
3 
4620.661 11545.938 1.000000 
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Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1814.349 469.858 0.026701  1813.112 62.900 0.010596  1813.880 136.470 0.012282 
2098.476 532.998 0.030289  2095.952 58.493 0.009854  2100.828 114.978 0.010348 4 
4620.624 17596.920 1.000000  
4 
4592.040 5935.993 1.000000  
4 
4621.916 11110.949 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1813.892 311.905 0.022459  1812.981 191.960 0.010131  1814.140 118.940 0.010558 
2098.476 376.980 0.027144  2099.178 168.957 0.008917  2098.583 82.980 0.007366 5 
4618.113 13887.908 1.000000  
5 
4618.950 18947.496 1.000000  
5 
4617.530 11265.707 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
1813.111 231.998 0.024781  1815.067 121.909 0.009325  1814.076 108.977 0.010773 
2098.757 283.992 0.030335  2100.090 119.990 0.009178  2098.654 75.952 0.007508 6 
4617.696 9361.806 1.000000  
6 
4621.039 13072.966 1.000000  
6 
4618.675 10116.107 1.000000 
              
Rel. Intens. Mean - 1807 0.024445  Rel. Intens. Mean - 1807 0.010048  Rel. Intens. Mean - 1807 0.010984 
Rel. Intens. Mean - 2092 0.028475  Rel. Intens. Mean - 2092 0.008624  Rel. Intens. Mean - 2092 0.009155 
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Appendix 3: Mass spectra of the replicate laser shots from PC2 enzyme activity assay. 
Blank spectra.  Front 2 spectra: sample with out PC2added.  Rear 2 spectra: sample with 
out ACTH 1-39 added.
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0.5 h pretreatment:  Blue – Control, Green – 10 µM, Red – 100 µM.
94 
 
1 h pretreatment:  Blue – Control, Green – 10 µM, Red – 100 µM.
95 
 
2 h pretreatment:  Blue – Control, Green – 10 µM, Red – 100 µM.
96 
 
3 h pretreatment:  Blue – Control, Green – 10 µM, Red – 100 µM.
97 
 
4 h pretreatment:  Blue – Control, Green – 10 µM, Red – 100 µM.
98 
 
Appendix 4: Summary of the mass spectral data from the PC2 enzyme activity assay. 
Control - 0.5hr Pretreatment - Rep 1  10µM - 0.5hr Pretreatment - Rep 1  100µM - 0.5hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.039 10976.844 6.802335  2095.876 16878.788 4.486737  2095.757 14256.191 4.379873 1 
4584.772 1613.688 1.000000  
1 
4585.894 3761.929 1.000000  
1 
4585.839 3254.933 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.677 10796.916 5.203422  2096.516 19625.895 5.569865  2096.275 19052.900 4.441494 2 
4586.012 2074.965 1.000000  
2 
4587.083 3523.586 1.000000  
2 
4586.724 4289.750 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.717 13046.850 6.636533  2096.556 14895.368 5.101315  2096.895 14590.319 4.418301 3 
4585.719 1965.913 1.000000  
3 
4587.316 2919.907 1.000000  
3 
4588.201 3302.247 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.997 13010.746 4.928566  2096.795 12333.689 5.818309  2097.354 10586.750 3.822577 4 
4586.901 2639.865 1.000000  
4 
4588.086 2119.806 1.000000  
4 
4588.671 2769.532 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.194 13395.323 5.731378  2097.035 11367.574 4.243490  2096.675 7626.750 5.060883 5 
4587.907 2337.191 1.000000  
5 
4588.492 2678.826 1.000000  
5 
4588.202 1507.000 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.035 10280.466 6.094512  2097.675 13167.695 4.484214  2097.316 9017.481 4.321245 6 
4587.844 1686.840 1.000000  
6 
4589.797 2936.455 1.000000  
6 
4588.983 2086.779 1.000000 
              
Control - 0.5hr Pretreatment - Rep 2  10µM - 0.5hr Pretreatment - Rep 2  100µM - 0.5hr Pretreatment - Rep 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.678 9726.731 7.162653  2095.916 18481.675 3.934998  2095.795 9608.650 4.335603 1 
4586.192 1357.979 1.000000  
1 
4586.724 4696.743 1.000000  
1 
4585.584 2216.220 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.238 8552.895 7.064363  2095.318 6023.931 4.315428  2096.077 9000.904 3.948713 2 
4585.127 1210.710 1.000000  
2 
4586.073 1395.906 1.000000  
2 
4586.248 2279.452 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.717 9095.717 5.274107  2096.836 28072.881 4.795822  2095.637 3808.886 4.992702 3 
4586.486 1724.599 1.000000  
3 
4588.142 5853.612 1.000000  
3 
4585.897 762.891 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.155 31245.251 6.054142  2096.355 26858.527 3.873483  2096.165 10637.253 4.870558 4 
4588.557 5160.971 1.000000  
4 
4586.961 6933.947 1.000000  
4 
4587.374 2183.990 1.000000 
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Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.874 11718.073 5.101638  2096.555 19253.300 3.942191  2096.636 9476.122 4.803546 5 
4589.323 2296.924 1.000000  
5 
4587.731 4883.909 1.000000  
5 
4587.963 1972.735 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2098.193 9929.851 5.757069  2097.514 25607.130 5.048843  2095.597 16601.771 5.369233 6 
4590.628 1724.810 1.000000  
6 
4589.857 5071.881 1.000000  
6 
4585.727 3092.019 1.000000 
              
Rel. Intens. Mean 5.984226  Rel. Intens. Mean 4.634558  Rel. Intens. Mean 4.563727 
 
Control - 1hr Pretreatment - Rep 1  10µM - 1hr Pretreatment - Rep 1  100µM - 1hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.236 32804.473 5.362952  2095.278 17175.550 4.207730  2096.436 10839.784 2.579940 1 
4587.140 6116.868 1.000000  
1 
4585.069 4081.904 1.000000  
1 
4587.144 4201.564 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.595 9736.487 5.055569  2096.236 13586.993 3.493774  2096.836 16448.655 2.781323 2 
4587.906 1925.893 1.000000  
2 
4586.963 3888.916 1.000000  
2 
4587.730 5913.967 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.834 11470.945 8.124178  2096.555 18588.668 3.251642  2097.873 11448.888 2.672048 3 
4587.964 1411.952 1.000000  
3 
4587.668 5716.702 1.000000  
3 
4589.681 4284.687 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2098.353 8170.980 6.125496  2095.322 6960.181 3.078471  2097.435 7680.818 2.886894 4 
4590.922 1333.929 1.000000  
4 
4585.126 2260.921 1.000000  
4 
4588.969 2660.582 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.675 6144.572 6.184553  2096.316 18091.461 3.464056  2097.394 12778.995 2.942632 5 
4590.448 993.535 1.000000  
5 
4587.373 5222.624 1.000000  
5 
4589.503 4342.709 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2098.633 11535.617 4.767610  2097.154 18954.524 3.930943  2097.913 16438.147 2.918007 6 
4591.042 2419.581 1.000000  
6 
4588.379 4821.877 1.000000  
6 
4589.977 5633.348 1.000000 
              
Control - 1hr Pretreatment - Rep 1  10µM - 1hr Pretreatment - Rep 2  100µM - 1hr Pretreatment - Rep 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.519 1642.313 8.643752  2095.398 7577.412 3.421964  2096.515 7583.101 3.178443 1 
4582.942 190.000 1.000000  
1 
4585.663 2214.346 1.000000  
1 
4587.848 2385.791 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.519 1818.697 7.188526  2095.078 4586.000 4.631430  2096.835 11584.917 3.461529 2 
4583.651 253.000 1.000000  
2 
4584.895 990.191 1.000000  
2 
4588.202 3346.763 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.800 3351.594 6.631905  2096.954 13736.852 4.397200  2094.798 1155.040 3.088342 3 
4584.184 505.374 1.000000  
3 
4588.497 3124.000 1.000000  
3 
4584.596 374.000 1.000000 
              
100 
 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.759 3320.700 7.536539  2097.633 8385.661 3.972976  2096.236 9567.969 3.596992 4 
4584.067 440.613 1.000000  
4 
4589.736 2110.675 1.000000  
4 
4586.960 2659.991 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.482 1472.389 5.252806  2097.515 2267.195 3.663299  2096.556 7080.943 3.365099 5 
4583.708 280.305 1.000000  
5 
4589.561 618.894 1.000000  
5 
4587.728 2104.230 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.680 2898.309 8.515447  2095.677 4875.996 4.152173  2095.757 10747.782 3.099226 6 
4583.883 340.359 1.000000  
6 
4585.832 1174.324 1.000000  
6 
4586.192 3467.892 1.000000 
              
Rel. Intens. Mean 6.615778  Rel. Intens. Mean 3.805472  Rel. Intens. Mean 3.047540 
 
Control - 2hr Pretreatment - Rep 1  10µM - 2hr Pretreatment - Rep 1  100µM - 2hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.389 9095.497 6.587671  2096.619 6577.941 1.787303  2096.899 3354.748 1.881853 1 
4587.730 1380.685 1.000000  
1 
4588.887 3680.373 1.000000  
1 
4589.656 1782.683 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.790 13435.868 4.514781  2096.619 9340.482 1.679960  2097.537 6798.639 2.003194 2 
4586.665 2975.973 1.000000  
2 
4589.123 5559.944 1.000000  
2 
4590.602 3393.899 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.311 18804.986 4.909194  2096.897 8847.439 1.920122  2094.980 3688.129 2.166460 3 
4585.836 3830.565 1.000000  
3 
4589.420 4607.747 1.000000  
3 
4585.934 1702.375 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.752 5104.865 5.943443  2097.577 3399.796 1.606789  2097.059 12538.950 1.832524 4 
4584.891 858.907 1.000000  
4 
4590.604 2115.894 1.000000  
4 
4590.131 6842.448 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.191 10249.834 4.704323  2098.537 7443.846 2.010386  2096.938 7225.544 1.972598 5 
4585.305 2178.812 1.000000  
5 
4592.322 3702.694 1.000000  
5 
4589.596 3662.958 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.670 14722.956 5.094479  2096.179 18487.940 1.963437  2097.377 9530.657 1.765979 6 
4587.020 2889.982 1.000000  
6 
4587.999 9416.109 1.000000  
6 
4590.425 5396.811 1.000000 
              
Control - 2hr Pretreatment - Rep 2  10µM - 2hr Pretreatment - Rep 2  100µM - 2hr Pretreatment - Rep 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.712 3070.887 5.214213  2096.938 4976.293 1.689332  2096.377 10000.992 1.371364 1 
4586.133 588.945 1.000000  
1 
4589.243 2945.716 1.000000  
1 
4587.821 7292.734 1.000000 
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Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.551 11660.684 8.619669  2097.499 4278.542 1.776455  2095.819 11325.009 1.620223 2 
4585.897 1352.800 1.000000  
2 
4589.893 2408.472 1.000000  
2 
4587.526 6989.785 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.711 11688.803 4.647649  2097.258 3263.927 1.610335  2096.978 12332.969 1.473308 3 
4586.665 2514.993 1.000000  
3 
4590.306 2026.862 1.000000  
3 
4589.301 8370.937 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.950 8993.896 4.406736  2098.576 16673.975 1.949262  2097.097 16124.832 1.396379 4 
4586.842 2040.943 1.000000  
4 
4592.555 8553.994 1.000000  
4 
4589.890 11547.603 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.148 6737.001 4.175580  2097.178 6634.143 1.916981  2097.257 11768.433 1.535248 5 
4588.793 1613.429 1.000000  
5 
4589.715 3460.724 1.000000  
5 
4589.714 7665.493 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.588 4100.564 4.613270  2097.017 4377.585 1.754740  2097.138 13033.905 1.408518 6 
4588.558 888.863 1.000000  
6 
4589.596 2494.720 1.000000  
6 
4590.247 9253.631 1.000000 
              
Rel. Intens. Mean 5.285917  Rel. Intens. Mean 1.805425  Rel. Intens. Mean 1.702304 
 
Control - 3hr Pretreatment - Rep 1  10µM - 3hr Pretreatment - Rep 1  100µM - 3hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.711 7090.718 5.741637  2095.831 1539.541 1.527984  2097.468 8461.958 1.335063 1 
4586.842 1234.965 1.000000  
1 
4586.841 1007.563 1.000000  
1 
4589.737 6338.249 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.750 6040.998 5.533166  2096.029 2281.592 1.728761  2097.907 8039.999 1.419302 2 
4586.605 1091.780 1.000000  
2 
4587.433 1319.784 1.000000  
2 
4590.154 5664.755 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.349 15263.716 5.784147  2096.429 10178.652 1.696201  2098.106 2217.936 1.501160 3 
4587.730 2638.888 1.000000  
3 
4588.203 6000.854 1.000000  
3 
4590.336 1477.481 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.268 5496.171 6.417145  2096.150 6412.127 1.690667  2095.351 7603.949 1.367260 4 
4589.210 856.482 1.000000  
4 
4587.966 3792.660 1.000000  
4 
4586.488 5561.452 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.427 6542.761 6.274923  2095.711 2153.161 1.621666  2095.152 4264.521 1.485934 5 
4589.739 1042.684 1.000000  
5 
4586.722 1327.747 1.000000  
5 
4585.485 2869.926 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.869 5438.989 6.443469  2096.509 4795.733 1.474358  2095.711 11020.434 1.292229 6 
4589.029 844.109 1.000000  
6 
4588.502 3252.759 1.000000  
6 
4586.789 8528.237 1.000000 
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Control - 3hr Pretreatment - Rep 2  10µM - 3hr Pretreatment - Rep 2  100µM - 3hr Pretreatment - Rep 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.829 9541.855 4.773409  2095.590 4560.756 1.634864  2095.631 1599.981 1.380816 1 
4588.084 1998.960 1.000000  
1 
4586.843 2789.686 1.000000  
1 
4586.369 1158.721 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.429 9492.856 5.722729  2096.310 5440.411 1.466216  2096.908 7766.907 1.567868 2 
4588.202 1658.799 1.000000  
2 
4587.908 3710.512 1.000000  
2 
4588.320 4953.802 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2097.228 6545.942 5.398980  2096.629 3588.858 1.488545  2097.188 1631.957 1.384967 3 
4589.621 1212.441 1.000000  
3 
4588.735 2410.984 1.000000  
3 
4589.083 1178.336 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.387 5457.743 4.756056  2097.028 3698.906 1.591842  2097.987 4708.950 1.402731 4 
4588.261 1147.536 1.000000  
4 
4588.678 2323.664 1.000000  
4 
4590.864 3356.987 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.595 6392.210 4.576664  2096.190 4263.919 1.444490  2098.786 11555.593 1.539841 5 
4588.028 1396.697 1.000000  
5 
4588.025 2951.851 1.000000  
5 
4592.344 7504.408 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.868 6849.326 4.967024  2096.949 3782.353 1.554808  2098.903 10741.928 1.289488 6 
4588.439 1378.960 1.000000  
6 
4588.440 2432.683 1.000000  
6 
4592.581 8330.384 1.000000 
              
Rel. Intens. Mean 5.532446  Rel. Intens. Mean 1.576700  Rel. Intens. Mean 1.413888 
 
Control - 4hr Pretreatment - Rep 1  10µM - 4hr Pretreatment - Rep 1  100µM - 4hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.471 5666.524 4.802370  2095.470 10491.574 1.779242  2096.749 10946.953 1.511623 1 
4585.659 1179.943 1.000000  
1 
4586.310 5896.652 1.000000  
1 
4589.267 7241.853 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2098.826 5041.317 4.512074  2095.391 9243.470 1.694225  2095.352 10504.654 1.378788 2 
4592.342 1117.295 1.000000  
2 
4586.191 5455.870 1.000000  
2 
4586.370 7618.761 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2099.313 9305.743 4.661012  2095.990 10431.371 1.719724  2095.431 10962.993 1.485305 3 
4593.054 1996.507 1.000000  
3 
4587.316 6065.725 1.000000  
3 
4586.310 7380.973 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2098.506 4078.953 4.823353  2096.270 6969.600 1.560276  2095.591 8880.849 1.378027 4 
4592.637 845.668 1.000000  
4 
4588.202 4466.903 1.000000  
4 
4586.369 6444.614 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2100.505 6615.437 5.092745  2096.749 7037.404 1.569466  2095.870 11092.888 1.330748 5 
4594.651 1298.992 1.000000  
5 
4588.676 4483.947 1.000000  
5 
4587.315 8335.826 1.000000 
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Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2100.304 4616.810 6.804373  2095.990 4078.897 1.594291  2096.868 18529.172 1.504249 6 
4594.473 678.506 1.000000  
6 
4587.551 2558.440 1.000000  
6 
4589.030 12317.885 1.000000 
              
Control - 4hr Pretreatment - Rep 2  10µM - 4hr Pretreatment - Rep 2  100µM - 4hr Pretreatment - Rep 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.311 4352.000 6.039167  2095.671 3355.945 1.820953  2096.828 6715.604 1.394360 1 
4585.836 720.629 1.000000  
1 
4586.902 1842.961 1.000000  
1 
4588.853 4816.263 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.550 5716.675 4.527333  2096.189 5700.405 1.642226  2096.669 5390.760 1.559854 2 
4586.019 1262.703 1.000000  
2 
4588.323 3471.144 1.000000  
2 
4588.971 3455.939 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.471 10108.518 4.560946  2096.190 8985.874 1.716450  2096.992 4681.457 1.568867 3 
4587.908 2216.320 1.000000  
3 
4588.084 5235.149 1.000000  
3 
4589.799 2983.974 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.152 3573.991 5.195154  2096.030 6424.563 1.561636  2097.269 6444.018 1.532902 4 
4585.365 687.947 1.000000  
4 
4587.611 4113.996 1.000000  
4 
4589.977 4203.802 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.349 5755.940 5.668231  2095.950 4353.808 1.761428  2097.387 4331.257 1.505552 5 
4588.439 1015.474 1.000000  
5 
4587.552 2471.748 1.000000  
5 
4589.740 2876.857 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.548 9650.981 6.754079  2097.108 10984.649 1.692895  2097.985 6321.008 1.413532 6 
4588.971 1428.912 1.000000  
6 
4589.561 6488.677 1.000000  
6 
4590.983 4471.782 1.000000 
              
Rel. Intens. Mean 5.286736  Rel. Intens. Mean 1.676068  Rel. Intens. Mean 1.463651 
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Appendix 5: Mass spectra of the replicate laser shots from oxime/PC2 enzyme activity 
assay. 
Oxime Treatment:  Yellow - ACTH Blank, Blue – Control 1, Grey – Control 2, Black – 
Control 3, Green – 50 µM oxime treatment, Red – 100 µM oxime treatment. 
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Appendix 6: Summary of the mass spectral data from the oxime/PC2 enzyme activity 
assay. 
Control 1 - Replicate 1  Control 2 - Replicate 1  Control 3 - Replicate 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.849 4765.979 6.859192  2094.691 5072.982 1.342093  2094.731 1157.972 6.812561 1 
4587.339 694.831 1.000000  
1 
4585.445 3779.904 1.000000  
1 
4585.269 169.976 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.210 6221.995 6.937638  2094.212 2340.908 1.279890  2094.851 3363.774 6.634667 2 
4585.328 896.846 1.000000  
2 
4583.791 1828.992 1.000000  
2 
4585.091 507.000 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.931 8914.987 5.002818  2094.292 697.976 1.504354  2096.488 2228.682 6.295713 3 
4585.032 1781.993 1.000000  
3 
4583.850 463.971 1.000000  
3 
4588.581 354.000 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.011 6321.976 5.186255  2095.330 4401.933 1.904419  2096.807 1236.999 6.280851 4 
4585.564 1218.987 1.000000  
4 
4585.800 2311.431 1.000000  
4 
4588.462 196.948 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.528 9618.940 6.365943  2094.731 3066.984 1.288111  2095.211 4208.723 6.447851 5 
4587.753 1511.000 1.000000  
5 
4585.564 2380.993 1.000000  
5 
4586.215 652.733 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2096.288 5285.909 6.771535  2095.090 4568.994 1.518452  2095.170 4292.981 6.456390 6 
4587.337 780.607 1.000000  
6 
4586.156 3008.981 1.000000  
6 
4585.860 664.920 1.000000 
              
Control 1 - Replicate 2  Control 2 - Replicate 2  Control 3 - Replicate 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.172 4588.961 5.976156  2095.011 1388.660 1.880301  2094.052 4705.925 6.536825 1 
4583.555 767.878 1.000000  
1 
4585.682 738.531 1.000000  
1 
4583.711 719.910 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.093 1720.988 5.814332  2094.611 692.386 1.408319  2095.010 3684.816 6.725168 2 
4583.318 295.991 1.000000  
2 
4585.329 491.640 1.000000  
2 
4585.565 547.914 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.811 6947.994 5.833887  2094.572 397.965 1.251936  2094.851 2952.996 6.826169 3 
4585.210 1190.972 1.000000  
3 
4585.563 317.880 1.000000  
3 
4585.501 432.599 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.330 7772.955 6.063199  2094.412 2582.472 1.933126  2094.611 2561.909 6.250950 4 
4585.860 1281.989 1.000000  
4 
4584.145 1335.905 1.000000  
4 
4584.735 409.843 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.410 4329.975 6.829829  2095.009 694.767 1.639052  2095.928 5871.988 6.369143 5 
4586.392 633.980 1.000000  
5 
4585.032 423.884 1.000000  
5 
4586.962 921.943 1.000000 
              
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.971 14103.351 4.955541  2094.491 1735.710 1.595337  2094.093 4021.988 6.032607 6 
4585.565 2845.976 1.000000  
6 
4584.737 1087.989 1.000000  
6 
4583.887 666.708 1.000000 
              
 Rel. Intens Mean 6.049694   Rel. Intens Mean 1.545449   Rel. Intens Mean 6.472408 
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50µM - Replicate 1  100µM - Replicate 1 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2093.973 1691.989 4.157327  2095.170 2511.974 4.794714 1 
4583.495 406.990 1.000000  
1 
4586.569 523.905 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.452 5128.957 4.328526  2095.729 6135.915 4.285153 2 
4584.677 1184.920 1.000000  
2 
4587.220 1431.901 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.170 3252.986 3.881974  2095.729 6030.838 5.106771 3 
4586.215 837.972 1.000000  
3 
4587.043 1180.949 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.931 3261.981 4.052305  2095.131 717.903 5.092190 4 
4585.328 804.969 1.000000  
4 
4585.979 140.981 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.571 2427.943 4.267568  2096.208 3045.713 4.432093 5 
4584.977 568.929 1.000000  
5 
4587.990 687.195 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.691 4783.899 4.061214  2095.809 1568.706 4.533994 6 
4584.973 1177.948 1.000000  
6 
4587.398 345.988 1.000000 
         
50µM - Replicate 2  100µM - Replicate 2 
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.250 2198.959 4.246344  2094.292 3329.883 5.076462 1 
4585.801 517.848 1.000000  
1 
4584.124 655.946 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.329 2069.474 4.038726  2094.492 2573.992 4.776527 2 
4586.334 512.408 1.000000  
2 
4584.361 538.884 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.530 1519.425 3.809487  2094.452 2661.966 4.301412 3 
4586.451 398.853 1.000000  
3 
4584.006 618.859 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.729 1054.893 4.187966  2094.452 2092.996 4.560111 4 
4587.339 251.887 1.000000  
4 
4584.361 458.979 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2094.771 4049.961 4.141942  2094.292 2296.827 4.930917 5 
4585.033 977.793 1.000000  
5 
4584.243 465.801 1.000000 
         
Shot m/z Intens. Rel. Intens.  Shot m/z Intens. Rel. Intens. 
2095.888 1523.912 4.282341  2094.811 2955.000 4.217246 6 
4587.397 355.860 1.000000  
6 
4584.245 700.694 1.000000 
         
 Rel. Intens Mean 4.121310   Rel. Intens Mean 4.675632 
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Appendix 7:  Representative spectra from the application of the PC2 enzyme activity 
assay on mouse urine in vitro.   
To test the PC2 enzyme assay’s robustness and application to an in vivo sample, 
several samples of mouse urine were obtained from Dr. Mariana Morris.  The urine was 
spun at ~16,000 G for 20 min.  In duplicate, 10 µL of the supernant was diluted in 90 µL 
of the PC2 activity assay buffer.  1 µL of 1 µg/µL ACTH 1-39 was added to each tube 
and samples were incubated at 37ºC for 5.5 h.  Additionally, sample blanks, 
buffer/ACTH blanks, buffer/PC2 blanks, and a PC2 activity assay control as described in 
the materials and method section were prepared and run as the samples.  Reactions were 
quenched by the addition of 10 µL of 10% TFA.  Each sample, blank and control 
preparation were spotted on weak-cation exchange protein chip array and analyzed as 
described in the material and methods section. 
The results from the analysis above revealed break down of the ACTH 1-39 in 
several samples.  However, none of the break down was a result of PC2 processing of 
ACTH 1-39 to ACTH 1-17.  See below for the MS. 
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Blank and control spectra.  Front 6 spectra: PC2 control as described in the materials and 
methods section.  Middle 2 spectra: sample with out ACTH 1-39 added.  Rear 2 spectra: 
sample with out PC2 added.
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STZ#1: Black spectra: sample with out ACTH 1-39 added.  Red: sample replicate 1. 
Blue: sample replicate 2.
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STZ#3: Black spectra: sample with out ACTH 1-39 added.  Red: sample replicate 1. 
Blue: sample replicate 2.
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STZ#8: Black spectra: sample with out ACTH 1-39 added.  Red: sample replicate 1. 
Blue: sample replicate 2.
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STZ#9: Black spectra: sample with out ACTH 1-39 added.  Red: sample replicate 1. 
Blue: sample replicate 2.   
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